<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children - Garegnani, L - 2021 | Cochrane Library</title> <meta content="Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children - Garegnani, L - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013757.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children - Garegnani, L - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013757.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013757.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children" name="citation_title"/> <meta content="Luis Garegnani" name="citation_author"/> <meta content="Instituto Universitario Hospital Italiano de Buenos Aires" name="citation_author_institution"/> <meta content="luisgaregnani@gmail.com" name="citation_author_email"/> <meta content="Lea Styrmisdóttir" name="citation_author"/> <meta content="Lund University" name="citation_author_institution"/> <meta content="Pablo Roson Rodriguez" name="citation_author"/> <meta content="Instituto Universitario Hospital Italiano" name="citation_author_institution"/> <meta content="Camila Micaela Escobar Liquitay" name="citation_author"/> <meta content="Instituto Universitario Hospital Italiano de Buenos Aires" name="citation_author_institution"/> <meta content="Ignacio Esteban" name="citation_author"/> <meta content="Juan VA Franco" name="citation_author"/> <meta content="Instituto Universitario Hospital Italiano de Buenos Aires" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013757.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/11/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013757.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013757.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013757.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Hospitalization; Length of Stay; Palivizumab [therapeutic use]; *Respiratory Syncytial Virus Infections [prevention &amp; control]; Respiratory Syncytial Viruses" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013757.pub2&amp;doi=10.1002/14651858.CD013757.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="77cjsSG8";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013757\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013757\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013757.pub2",title:"Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children",firstPublishedDate:"Nov 16, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013757.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013757.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013757.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013757.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013757.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013757.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013757.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013757.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013757.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013757.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8411 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013757.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full#CD013757-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full#CD013757-sec-0075"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full#CD013757-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full#CD013757-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full#CD013757-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full#CD013757-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full#CD013757-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full#CD013757-sec-0069"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/appendices#CD013757-sec-0080"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/supinfo/CD013757StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/supinfo/CD013757StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/information#CD013757-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Luis Garegnani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/information#CD013757-cr-0005">Lea Styrmisdóttir</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/information#CD013757-cr-0006">Pablo Roson Rodriguez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/information#CD013757-cr-0007">Camila Micaela Escobar Liquitay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/information#CD013757-cr-0008">Ignacio Esteban</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013757.pub2/information#CD013757-cr-0009">Juan VA Franco</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/information/en#CD013757-sec-0092">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 November 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013757.pub2">https://doi.org/10.1002/14651858.CD013757.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013757-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013757-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013757-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013757-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013757-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013757-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013757-abs-0001" lang="en"> <section id="CD013757-sec-0001"> <h3 class="title" id="CD013757-sec-0001">Background</h3> <p>Respiratory viruses are the leading cause of lower respiratory tract infection (LRTI) and hospitalisation in infants and young children. Respiratory syncytial virus (RSV) is the main infectious agent in this population. Palivizumab is administered intramuscularly every month during five months in the first RSV season to prevent serious RSV LRTI in children. Given its high cost, it is essential to know if palivizumab continues to be effective in preventing severe RSV disease in children. </p> </section> <section id="CD013757-sec-0002"> <h3 class="title" id="CD013757-sec-0002">Objectives</h3> <p>To assess the effects of palivizumab for preventing severe RSV infection in children.</p> </section> <section id="CD013757-sec-0003"> <h3 class="title" id="CD013757-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, three other databases and two trials registers to 14 October 2021, together with reference checking, citation searching and contact with study authors to identify additional studies. We searched Embase to October 2020, as we did not have access to this database for 2021. </p> </section> <section id="CD013757-sec-0004"> <h3 class="title" id="CD013757-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs), including cluster‐RCTs, comparing palivizumab given at a dose of 15 mg/kg once a month (maximum five doses) with placebo, no intervention or standard care in children 0 to 24 months of age from both genders, regardless of RSV infection history.  </p> </section> <section id="CD013757-sec-0005"> <h3 class="title" id="CD013757-sec-0005">Data collection and analysis</h3> <p>We used Cochrane’s Screen4Me workflow to help assess the search results. Two review authors screened studies for selection, assessed risk of bias and extracted data. We used standard Cochrane methods. We used GRADE to assess the certainty of the evidence. The primary outcomes were hospitalisation due to RSV infection, all‐cause mortality and adverse events. Secondary outcomes were hospitalisation due to respiratory‐related illness, length of hospital stay, RSV infection, number of wheezing days, days of supplemental oxygen, intensive care unit length of stay and mechanical ventilation days. </p> </section> <section id="CD013757-sec-0006"> <h3 class="title" id="CD013757-sec-0006">Main results</h3> <p>We included five studies with  a total of 3343 participants. All studies were parallel RCTs, assessing the effects of 15 mg/kg of palivizumab every month up to five months compared to placebo or no intervention in an outpatient setting, although one study also included hospitalised infants. Most of the included studies were conducted in children with a high risk of RSV infection due to comorbidities like bronchopulmonary dysplasia and congenital heart disease. The risk of bias of outcomes across all studies was similar and predominately low.  </p> <p>Palivizumab reduces hospitalisation due to RSV infection at two years' follow‐up (risk ratio (RR) 0.44, 95% confidence interval (CI) 0.30 to 0.64; 5 studies, 3343 participants; high certainty evidence). Based on 98 hospitalisations per 1000 participants in the placebo group, this corresponds to 43 (29 to 62) per 1000 participants in the palivizumab group. Palivizumab probably results in little to no difference in mortality at two years' follow‐up (RR 0.69, 95% CI 0.42 to 1.15; 5 studies, 3343 participants; moderate certainty evidence). Based on 23 deaths per 1000 participants in the placebo group, this corresponds to 16 (10 to 27) per 1000 participants in the palivizumab group. Palivizumab probably results in little to no difference in adverse events at 150 days' follow‐up (RR 1.09, 95% CI 0.85 to 1.39; 3 studies, 2831 participants; moderate certainty evidence). Based on 84 cases per 1000 participants in the placebo group, this corresponds to 91 (71 to 117) per 1000 participants in the palivizumab group. Palivizumab probably results in a slight reduction in hospitalisation due to respiratory‐related illness at two years' follow‐up (RR 0.78, 95% CI 0.62 to 0.97; 5 studies, 3343 participants; moderate certainty evidence). Palivizumab may result in a large reduction in RSV infection at two years' follow‐up (RR 0.33, 95% CI 0.20 to 0.55; 3 studies, 554 participants; low certainty evidence). Based on 195 cases of RSV infection per 1000 participants in the placebo group, this corresponds to 64 (39 to 107) per 1000 participants in the palivizumab group. Palivizumab also reduces the number of wheezing days at one year's follow‐up (RR 0.39, 95% CI 0.35 to 0.44; 1 study, 429 participants; high certainty evidence). </p> </section> <section id="CD013757-sec-0007"> <h3 class="title" id="CD013757-sec-0007">Authors' conclusions</h3> <p>The available evidence suggests that prophylaxis with palivizumab reduces hospitalisation due to RSV infection and results in little to no difference in mortality or adverse events. Moreover, palivizumab results in a slight reduction in hospitalisation due to respiratory‐related illness and may result in a large reduction in RSV infections. Palivizumab also reduces the number of wheezing days. These results may be applicable to children with a high risk of RSV infection due to comorbidities. </p> <p>Further research is needed to establish the effect of palivizumab on children with other comorbidities known as risk factors for severe RSV disease (e.g. immune deficiencies) and other social determinants of the disease, including children living in low‐ and middle‐income countries, tropical regions, children lacking breastfeeding, living in poverty, or members of families in overcrowded situations.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013757-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013757-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013757-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013757-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013757-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013757-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013757-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013757-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013757-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013757-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013757-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013757-abs-0002" lang="en"> <h3>Palivizumab for respiratory syncytial virus infection prevention in children</h3> <p><b>Review question</b> </p> <p>What are the effects (benefits and harms) of palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children? </p> <p><b>Background</b> </p> <p>RSV is the main cause of acute respiratory infections in children, mainly during the first year of life, accounting for 33.1 million infections a year with an estimated 90.6% of these episodes occurring in low‐ and middle‐income countries. These infections may present with a runny nose, fever, cough, shortness of breath, wheezing, or difficulty feeding. They may result in hospitalisation, admission to an intensive care unit, and even death, in particular amongst infants aged less than two months, with an estimated hospitalisation rate of 1970 per 100,000 population and 59,600 deaths annually worldwide in children younger than five years old. They may also lead to long‐term complications such as recurrent wheezing and chronic lung problems.  </p> <p>Palivizumab, sold under the brand name Synagis, is a drug administered with an intramuscular injection every month up to five doses to prevent serious infections in children at high risk for severe disease. </p> <p><b>Search date</b> </p> <p>The evidence is current to 14 October 2021.</p> <p><b>Study characteristics</b> </p> <p>We included five studies with 3343 participants. All studies included a small number of participants, including children with a high risk of adverse outcomes if infected with RSV due to underlying health issues, such as premature birth or heart or pulmonary problems.    </p> <p><b>Study funding sources</b> </p> <p>Most studies did not specify their funding sources. One study was funded by Abbott Laboratories and by the Netherlands Organisation for Health Research and Development.  </p> <p><b>Key results</b> </p> <p>Palivizumab reduces hospitalisation due to RSV infection by 56%; based on 98 cases per 1000 participants in the placebo group, this corresponds to 43 per 1000 participants in the palivizumab group. Palivizumab probably results in little to no difference in mortality, and little to no difference in adverse events; based on 23 deaths per 1000 participants and 84 adverse events per 1000 participants in the placebo group, this corresponds to 16 deaths per 1000 participants and 81  adverse events per 1000 participants in the palivizumab group. Palivizumab probably results in a slight reduction in hospitalisation due to respiratory illness by 22% but may result in little to no difference in length of hospital stay. It may reduce RSV infection rate by 67% at two years’ follow‐up. Palivizumab also reduces the number of wheezing days by 61% but may result in little to no difference in days using oxygen, length of stay in the intensive care unit, or mechanical ventilation days.  </p> <p><b>Certainty of the evidence</b> </p> <p>The overall certainty of the evidence was moderate to high. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013757-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013757-sec-0075"></div> <h3 class="title" id="CD013757-sec-0076">Implications for practice</h3> <section id="CD013757-sec-0076"> <p>The available evidence suggests that prophylaxis with palivizumab reduces hospitalisation due to respiratory syncytial virus (RSV) infection and results in little to no difference in mortality or adverse events. Moreover, palivizumab results in a slight reduction in hospitalisation due to respiratory‐related illness and may result in a large reduction in severe RSV infections. Palivizumab also reduces the number of wheezing days. Despite our aim to determine the effect of palivizumab for preventing severe RSV infection in all children, no studies were found on healthy children without a higher risk for RSV life‐threatening disease or with immunodeficiency disorders, as all of the included studies were carried out in high‐risk populations.  </p> </section> <h3 class="title" id="CD013757-sec-0077">Implications for research</h3> <section id="CD013757-sec-0077"> <p>Further research is needed to establish the effect of palivizumab on children with other comorbidities known as risk factors for severe RSV disease (e.g. immune deficiencies) and other social determinants of the disease, including children living in low‐ and middle‐income countries, tropical regions, children lacking breastfeeding, living in poverty, or members of families in overcrowded situations. Further research must consider the cost of the intervention in relation to the potential benefits arising from extended use and the subsequent impact on equity.  </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013757-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013757-sec-0008"></div> <div class="table" id="CD013757-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Palivizumab compared to placebo, no intervention or standard care for preventing respiratory syncytial virus (RSV) infection in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Palivizumab compared to placebo, no intervention or standard care for preventing respiratory syncytial virus (RSV) infection in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children (0 to 24 months) </p> <p><b>Setting</b>: inpatients and outpatients </p> <p><b>Intervention</b>: palivizumab   </p> <p><b>Comparison</b>: placebo, no intervention or standard care   </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Outcomes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Relative effect<br/>(95% CI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>№ of participants<br/>(studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Certainty of the evidence<br/>(GRADE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Comments</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with palivizumab</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospitalisation due to RSV infection</b> </p> <p><i>Follow‐up:  2 years</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>98 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b><br/>(29 to 62) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.44</b><br/>(0.30 to 0.64) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3343<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁⨁<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> <p><i>Follow‐up:  2 years</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b><br/>(10 to 27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.69</b><br/>(0.42 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3343<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁◯<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p><i>Follow‐up: 150 days</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>84 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b><br/>(71 to 117) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.09</b><br/>(0.85 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2831<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁◯<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospitalisation due to respiratory‐related illness</b> </p> <p><i>Follow‐up: 2 years</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>351 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>274 per 1000</b><br/>(218 to 340) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.78</b><br/>(0.62 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3343<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁◯<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RSV infection</b> </p> <p><i>Assessed with: incidence of laboratory‐confirmed RSV‐bronchiolitis</i> </p> <p><i>Follow‐up: 2 years</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>195 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b><br/>(39 to 107) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.33</b><br/>(0.20 to 0.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>554<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁◯◯<br/>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of wheezing days</b> </p> <p><i>Assessed with: rates of wheezing per day</i> </p> <p><i>Follow‐up: 12 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>45 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b><br/>(16 to 19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.39</b><br/>(0.35 to 0.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁⨁<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level due to imprecision. The 95% confidence interval includes appreciable benefit and little to no effect.<br/><sup>b</sup>Downgraded 1 level due to imprecision. The 95% confidence interval includes appreciable benefit and harm.<br/><sup>c</sup>Downgraded 2 levels due to few number of events and participants in both groups. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013757-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013757-sec-0009"></div> <section id="CD013757-sec-0010"> <h3 class="title" id="CD013757-sec-0010">Description of the condition</h3> <p>Respiratory viruses are the leading cause of lower respiratory tract infection (LRTI) and hospitalisation in infants and young children (<a href="./references#CD013757-bbs2-0076" title="NairH , NokesDJ , GessnerBD , DheraniM , MadhiSA , SingletonRJ , et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet2010;375(9725):1545-55.">Nair 2010</a>; <a href="./references#CD013757-bbs2-0077" title="NairH , BrooksWA , KatzM , RocaA , BerkleyJA , MadhiSA , et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet2011;378(9807):1917-30.">Nair 2011</a>). Globally, respiratory syncytial virus (RSV) is the main infectious agent every year in this population (<a href="./references#CD013757-bbs2-0076" title="NairH , NokesDJ , GessnerBD , DheraniM , MadhiSA , SingletonRJ , et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet2010;375(9725):1545-55.">Nair 2010</a>; <a href="./references#CD013757-bbs2-0093" title="ShiT , McAllisterDA , O'BrienKL , SimoesEA , MadhiSA , GessnerBD , et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet2017;390(10098):946-58.">Shi 2017</a>). Over the past 15 years, there has been a significant reduction in child pneumonia mortality and morbidity due to the successful implementation of new vaccine schedules for <i>Haemophilus influenzae</i> and <i>Streptococcus pneumoniae</i> (<a href="./references#CD013757-bbs2-0093" title="ShiT , McAllisterDA , O'BrienKL , SimoesEA , MadhiSA , GessnerBD , et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet2017;390(10098):946-58.">Shi 2017</a>). In this context of scale‐up in vaccines, the burden of RSV disease continues to increase (<a href="./references#CD013757-bbs2-0093" title="ShiT , McAllisterDA , O'BrienKL , SimoesEA , MadhiSA , GessnerBD , et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet2017;390(10098):946-58.">Shi 2017</a>). </p> <p>RSV, now reclassified as a member of the <i>Pneumoviridae</i> family and <i>Orthopneumovirus</i> genus (<a href="./references#CD013757-bbs2-0020" title="AmarasingheGK , AyllónMA , BàoY , BaslerCF , BavariS , BlasdellKR . Taxonomy of the order mononegavirales: update 2019. Archives of Virology2019;164(7):1967-80.">Amarasinghe 2019</a>), was first identified in 1956 (<a href="./references#CD013757-bbs2-0033" title="ChanockR , RoizmanB , MyersR . Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. American Journal of Hygiene1957;66(3):281-90.">Chanock 1957</a>). Its viral genome, a single‐stranded and negative sensed ribonucleic acid (RNA), codes for 11 proteins (nine structural proteins and two non‐structural proteins) (<a href="./references#CD013757-bbs2-0045" title="GálvezNM , SotoJA , KalergisAM . New insights contributing to the development of effective vaccines and therapies to reduce the pathology caused by hRSV. International Journal of Molecular Sciences2017;18(8):1753.">Gálvez 2017</a>; <a href="./references#CD013757-bbs2-0051" title="HackingD , HullJ . Respiratory syncytial virus-viral biology and the host response. Journal of Infection2002;45(1):18-24.">Hacking 2002</a>). Transmission of the virus occurs mainly due to contact with contaminated secretions, including surfaces (where RSV can survive for several hours), hands, and direct contact with respiratory secretions. Inoculation develops in the upper respiratory tract, with subsequent infection of the respiratory epithelium, triggering the main infectious mechanisms to survive. Once infected, the incubation period may last four to five days (<a href="./references#CD013757-bbs2-0066" title="LesslerJ , ReichNG , BrookmeyerR , PerlTM , NelsonKE , CummingsDA . Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infectious Diseases2009;9(5):291-300.">Lessler 2009</a>). </p> <p>The seasonality of RSV infection varies according to the location, with considerable fluctuations each year (<a href="./references#CD013757-bbs2-0075" title="MullinsJA , LamonteAC , BreseeJS , AndersonLJ . Substantial variability in community respiratory syncytial virus season timing. Pediatric Infectious Disease Journal2003;22(10):857-63.">Mullins 2003</a>). Understanding RSV seasonality has become essential in order to determine the month in which to start immunoprophylaxis for vulnerable populations. In temperate climates, there is a clear affinity for colder seasons (Northern Hemisphere: November to April; Southern Hemisphere: April to September). However, in regions with tropical and subtropical climates, RSV may be present throughout the whole year, probably correlating with rainy seasons (<a href="./references#CD013757-bbs2-0029" title="BradyMT ,  Byington CL, DaviesHD , EdwardsKM , JacksonMA ,  Maldonado YA, et al, on behalf of American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics2014;134(2):415-20.">Brady 2014</a>; <a href="./references#CD013757-bbs2-0052" title="HallCB , WeinbergGA , IwaneMK , BlumkinAK , EdwardsKM , StaatMA , et al. The burden of respiratory syncytial virus infection in young children. New England Journal of Medicine.2009;360(6):588-98.">Hall 2009</a>). </p> <p>In the USA, RSV is one of the main causes of hospitalisation, in particular amongst infants aged less than two months, with an estimated hospitalisation rate of 1970 per 100,000 population (95% confidence interval (CI), 1787 to 2177) (<a href="./references#CD013757-bbs2-0024" title="ArriolaCS , KimL , LangleyG , AndersonEJ , OpenoK , MartinAM , et al. Estimated burden of community-onset respiratory syncytial virus associated hospitalizations among children aged &lt;2 years in the United States, 2014-15. Journal of the Pediatric Infectious Diseases Society2019;9(5):587-95. [DOI: 10.1093/jpids/piz087] [PMID: 31868913]">Arriola 2019</a>). Furthermore, RSV infected children in the USA, present a higher average of all‐cause cumulative hospitalisations rates, for at least five years after the initial infection (<a href="./references#CD013757-bbs2-0097" title="SimõesEA , ChirikovV , BottemanM , KwonY , KuznikA . Long-term assessment of healthcare utilization 5 years after respiratory syncytial virus infection in US infants. Journal of Infectious Diseases2020;221(8):1256-70. [PMID: 31165865]">Simões 2020</a>). However, the burden of the disease, the number of infected per total population, and the short‐ and long‐term complications are considerably lower in high‐income countries (HIC) (<a href="./references#CD013757-bbs2-0024" title="ArriolaCS , KimL , LangleyG , AndersonEJ , OpenoK , MartinAM , et al. Estimated burden of community-onset respiratory syncytial virus associated hospitalizations among children aged &lt;2 years in the United States, 2014-15. Journal of the Pediatric Infectious Diseases Society2019;9(5):587-95. [DOI: 10.1093/jpids/piz087] [PMID: 31868913]">Arriola 2019</a>; <a href="./references#CD013757-bbs2-0093" title="ShiT , McAllisterDA , O'BrienKL , SimoesEA , MadhiSA , GessnerBD , et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet2017;390(10098):946-58.">Shi 2017</a>). In the Western Pacific Region, the incidence of RSV hospitalisation ranged between 4.9 and 30.9 per 1000 child‐years, varying according to age group (<a href="./references#CD013757-bbs2-0081" title="PangestiKN , El GhanyMA , KessonAM , Hill-CawthorneGA . Respiratory syncytial virus in the Western Pacific Region: a systematic review and meta-analysis. Journal of Global Health2019;9(2):020431.">Pangesti 2019</a>).  </p> <p>Globally, RSV accounts for 33.1 million (uncertainty range (UR) 21.6 to 50.3) LRTI a year in children younger than five years old, mainly during the first year of life (<a href="./references#CD013757-bbs2-0093" title="ShiT , McAllisterDA , O'BrienKL , SimoesEA , MadhiSA , GessnerBD , et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet2017;390(10098):946-58.">Shi 2017</a>), with an estimate of 90.6% (30.0 million) of these episodes occurring in low‐ and middle‐income countries (LMIC) (<a href="./references#CD013757-bbs2-0093" title="ShiT , McAllisterDA , O'BrienKL , SimoesEA , MadhiSA , GessnerBD , et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet2017;390(10098):946-58.">Shi 2017</a>). More than three million (UR 2.7 to 3.8) hospital admissions worldwide in young children are due to RSV LRTI, with the highest rate in children younger than six months old, in particular in neonates with 15.9 (95% CI 8.8 to 28.9) admissions per year in LMIC (<a href="./references#CD013757-bbs2-0076" title="NairH , NokesDJ , GessnerBD , DheraniM , MadhiSA , SingletonRJ , et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet2010;375(9725):1545-55.">Nair 2010</a>; <a href="./references#CD013757-bbs2-0093" title="ShiT , McAllisterDA , O'BrienKL , SimoesEA , MadhiSA , GessnerBD , et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet2017;390(10098):946-58.">Shi 2017</a>). Severe RSV LRTI (hypoxaemia) accounts for 1.0 million (UR 0.6 to 1.6) hospital admissions, and very severe LRTI (hospitalised LRTI with danger signs like cyanosis, difficulty in breastfeeding or drinking, vomiting, convulsions, lethargy, unconsciousness, head nodding or ICU admission/mechanical ventilation) for 0.6 million (UR 0.4 to 1) every year in LMIC, mostly in children younger than six months old (<a href="./references#CD013757-bbs2-0093" title="ShiT , McAllisterDA , O'BrienKL , SimoesEA , MadhiSA , GessnerBD , et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet2017;390(10098):946-58.">Shi 2017</a>). </p> <p>Regarding mortality, RSV is one of the leading causes of death in the paediatric population (<a href="./references#CD013757-bbs2-0089" title="ScheltemaNM , GentileA , LucionF , NokesDJ , MunywokiPK , MadhiSA , et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet2017;5(10):e984-91.">Scheltema 2017</a>; <a href="./references#CD013757-bbs2-0111" title="World Health Organization. World Health Statistics 2018: monitoring health for the SDGs. www.who.int/gho/publications/world_health_statistics/2018/en/.">WHO 2018</a>), with a worldwide annual estimate of 59,600 fatalities (UR 48,000 to 74,500) in children younger than five years old (<a href="./references#CD013757-bbs2-0078" title="NairH , SimõesEA , RudanI , GessnerBD , Azziz-BaumgartnerE , ZhangJS , et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet2013;381(9875):1380-90.">Nair 2013</a>). Most deaths occur in previously healthy children, in particular, in LMIC (<a href="./references#CD013757-bbs2-0046" title="GeogheganS , ErvitiA , CaballeroMT , ValloneF , ZanoneSM , LosadaJV , et al. Mortality due to respiratory syncytial virus. Burden and risk factors. American Journal of Respiratory and Critical Care Medicine2017;195(1):96-103.">Geoghegan 2017</a>; <a href="./references#CD013757-bbs2-0052" title="HallCB , WeinbergGA , IwaneMK , BlumkinAK , EdwardsKM , StaatMA , et al. The burden of respiratory syncytial virus infection in young children. New England Journal of Medicine.2009;360(6):588-98.">Hall 2009</a>; <a href="./references#CD013757-bbs2-0053" title="HallCB , WeinbergGA , BlumkinAK , EdwardsKM , StaatMA , SchultzAF , et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics2013;132(2):341-8.">Hall 2013</a>). In HIC, mortality cases are usually in older children who have a higher prevalence of comorbidities (7.0 years interquartile range (IQR) 3.6 to 16.8 and 70%, respectively) than in upper middle‐income countries (4 years IQR 2.0 to 10.0 and 47%) and LMIC (5 months IQR 2.3 to 11.0 and 28%) (<a href="./references#CD013757-bbs2-0089" title="ScheltemaNM , GentileA , LucionF , NokesDJ , MunywokiPK , MadhiSA , et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet2017;5(10):e984-91.">Scheltema 2017</a>). As expected, the case fatality rate is higher in children with comorbidities, in particular, those with chronic lung diseases, congenital heart disease, premature birth, Down's syndrome, and a diagnosis of sepsis or pneumothorax during hospitalisation (<a href="./references#CD013757-bbs2-0046" title="GeogheganS , ErvitiA , CaballeroMT , ValloneF , ZanoneSM , LosadaJV , et al. Mortality due to respiratory syncytial virus. Burden and risk factors. American Journal of Respiratory and Critical Care Medicine2017;195(1):96-103.">Geoghegan 2017</a>; <a href="./references#CD013757-bbs2-0064" title="LeeYI , PengCC , ChiuNC , HuangDT , HuangFY , ChiH . Risk factors associated with death in patients with severe respiratory syncytial virus infection. Journal of Microbiology, Immunology, and Infection2016;49(5):737-42.">Lee 2016</a>; <a href="./references#CD013757-bbs2-0105" title="ThorburnK . Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Archives of Disease in Childhood2009;94(2):99-103.">Thorburn 2009</a>; <a href="./references#CD013757-bbs2-0110" title="Welliver RC Sr, ChecchiaPA , BaumanJH , FernandesAW , MahadeviaPJ , HallCB . Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Current Medical Research and Opinion2010;26(9):2175-81.">Welliver 2010</a>). To add to this burden of disease of RSV LRTI, there is a considerable proportion of children who die at home without being hospitalised, in particular in LMIC, a reflection of limited access to hospital care (<a href="./references#CD013757-bbs2-0030" title="CaballeroMT , BianchiAM , NuñoA , FerrettiAJ , PolackLM , RemondinoI . Mortality associated with acute respiratory infections among children at home. Journal of Infectious Diseases2019;219(3):358-64.">Caballero 2019</a>; <a href="./references#CD013757-bbs2-0093" title="ShiT , McAllisterDA , O'BrienKL , SimoesEA , MadhiSA , GessnerBD , et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet2017;390(10098):946-58.">Shi 2017</a>).  </p> <p>RSV infection has a significant economic burden on the health system, for example, in the USA, the total annual direct medical costs for all RSV infections in children younger than five years old is USD 652 million per year (USD 394 million from hospitalisations and USD 258 million from other medical encounters) (<a href="./references#CD013757-bbs2-0082" title="ParamoreLC , CiurylaV , CieslaG , LiuL . Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. PharmacoEconomics2004;22(5):275-84.">Paramore 2004</a>). In LMIC, the cost of each RSV episode is less expensive, but due to the larger proportion of RSV infections, the economic burden may be more significant (<a href="./references#CD013757-bbs2-0115" title="ZhangS , SammonPM , KingI , AndradeAL , ToscanoCM , AraujoSN , et al. Cost of management of severe pneumonia in young children: systematic analysis. Journal of Global Health2016;6(1):010408.">Zhang 2016</a>). </p> <p>At an individual level, almost every child has been infected with the virus by the age of two years (<a href="./references#CD013757-bbs2-0043" title="FeldmanAS , HeY , MooreML , HershensonMB , HartertTV . Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. American Journal of Respiratory and Critical Care Medicine2015;191(1):34-44.">Feldman 2015</a>; <a href="./references#CD013757-bbs2-0059" title="HolbergCJ , WrightAL , MartinezFD , RayCG , TaussigLM , LebowitzMD . Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. American Journal of Epidemiology1991;133(11):1135-51. [PMID: 2035517]">Holberg 1991</a>). Signs and symptoms range from an upper respiratory tract infection (nasal congestion, fever, cough, rhinorrhoea) or a LRTI (bronchiolitis or pneumonia) with difficulty breathing, wheezing, difficulty in feeding, or apnoea (<a href="./references#CD013757-bbs2-0023" title="ArmsJL , OrtegaH , ReidS . Chronological and clinical characteristics of apnea associated with respiratory syncytial virus infection: a retrospective case series. Clinical Pediatrics2008;47(9):953-8.">Arms 2008</a>; <a href="./references#CD013757-bbs2-0040" title="DomachowskeJB , RosenbergHF . Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clinical Microbiology Reviews1999;12(2):298-309.">Domachowske 1999</a>). Severity depends on the damage inflicted by the virus and the efficiency of the triggered immune response. Most children will only require ambulatory management, and only a few will need admission to a general ward (1% to 3%) <a href="./references#CD013757-bbs2-0028" title="BoyceTG , MellenBG , Mitchel EF Jr, WrightPF , GriffinMR . Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. Journal of Pediatrics2000;137(6):865-70.">Boyce 2000</a>, or an ICU (less than 1%) (<a href="./references#CD013757-bbs2-0027" title="BontL , ChecchiaPA , FaurouxB ,  Figueras-AloyJ , ManzoniP , PaesB , et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in Western countries. Infectious Diseases and Therapy2016;5(3):271-98.">Bont 2016</a>; <a href="./references#CD013757-bbs2-0055" title="HervásD , ReinaJ , YañezA , delValleJM , FiguerolaJ , HervásJA . Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. European Journal of Clinical Microbiology &amp; Infectious Diseases2012;31(8):1975-81.">Hervás 2012</a>; <a href="./references#CD013757-bbs2-0092" title="ShayDK , HolmanRC , RooseveltGE , ClarkeMJ , AndersonLJ . Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. Journal of Infectious Diseases2001;183(1):16-22.">Shay 2001</a>). Children at higher risk for RSV life‐threatening disease include those with congenital heart disease, preterm birth, chronic lung disease, pulmonary hypertension and immunodeficiency (<a href="./references#CD013757-bbs2-0039" title="DamoreD , MansbachJM , ClarkS , RamundoM , Camargo CA Jr. Prospective multicenter bronchiolitis study: predicting intensive care unit admissions. Academic Emergency Medicine2008;15(10):887-94.">Damore 2008</a>; <a href="./references#CD013757-bbs2-0069" title="MansbachJM , PiedraPA , StevensonMD , SullivanAF ,  MARC-30 Investigators. Prospective multicenter study of children with bronchiolitis requiring mechanical ventilation. Pediatrics2012;130(3):e492-500.">Mansbach 2012</a>; <a href="./references#CD013757-bbs2-0083" title="PurcellK , FergieJ . Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatric Infectious Disease Journal2004;23(5):418-23.">Purcell 2004</a>). RSV infections in children, in particular those episodes requiring hospitalisation, are associated not only with acute complications but also with long‐term complications such as recurrent wheezing, impaired lung function and paediatric asthma (<a href="./references#CD013757-bbs2-0041" title="EstebanI , SteinRT , PolackFP . A durable relationship: respiratory syncytial virus bronchiolitis and asthma past their golden anniversary. Vaccines2020;8(2):E201.">Esteban 2020</a>; <a href="./references#CD013757-bbs2-0042" title="Fauroux B, SimõesEA , ChecchiaPA , PaesB , Figueras-AloyJ , ManzoniP , et al. The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infectious Diseases and Therapy2017;6(2):173-97.">Fauroux 2017</a>; <a href="./references#CD013757-bbs2-0094" title="SigursN , GustafssonPM , BjarnasonR , LundbergF , SchmidtS , SigurbergssonF , et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. American Journal of Respiratory and Critical Care Medicine2005;171(2):137-41.">Sigurs 2005</a>; <a href="./references#CD013757-bbs2-0098" title="SinghAM , MoorePE , GernJE , Lemanske RF Jr, HartertTV . Bronchiolitis to asthma: a review and call for studies of gene-virus interactions in asthma causation. American Journal of Respiratory and Critical Care Medicine2007;175(2):108-19.">Singh 2007</a>; <a href="./references#CD013757-bbs2-0104" title="ThomsenSF , van derSluisS , StensballeLG , PosthumaD , SkyttheA , KyvikKO , et al. Exploring the association between severe respiratory syncytial virus infection and asthma: a registry-based twin study. American Journal of Respiratory and Critical Care Medicine2009;179(12):1091-7.">Thomsen 2009</a>).  </p> </section> <section id="CD013757-sec-0011"> <h3 class="title" id="CD013757-sec-0011">Description of the intervention</h3> <p>Palivizumab is a humanised monoclonal antibody (mAb) against RSV fusion (F) glycoprotein, inhibiting RSV replication (<a href="./references#CD013757-bbs2-0061" title="JohnsonS , OliverC , PrinceGA , HemmingVG , PfarrDS ,  WangSC , et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. Journal of Infectious Diseases1997;176(5):1215-24.">Johnson 1997</a>). It was first licenced under the name of Synagis in the USA. Trials were first conducted in 1996, published in 1998 with subsequent Food and Drug Administration (FDA) approval, proving safety and efficacy in highly vulnerable conditions (premature children born before 35 weeks and children with bronchopulmonary dysplasia) (IMpact‐RSV Study Group 1998). Following approval by the European Medicines Agency in 1999, the use of the drug became worldwide (<a href="./references#CD013757-bbs2-0102" title="SYNAGIS ® (palivizumab). www.ema.europa.eu/en/medicines/human/EPAR/synagis#overview-section (accessed 5 May 2020).">SYNAGIS ® (palivizumab)</a>).  </p> <p>The drug is administered intramuscularly on a monthly basis during the infant’s first RSV season (up to five doses at a dose of 15 mg/kg) to prevent serious RSV LRTI. In some cases, children with bronchopulmonary dysplasia or congenital heart disease receive a second season of the drug. Monoclonal antibodies promote a response that depends entirely from the given half‐life of the antibody in the host, without activating the immune system or inducing immunological memory, hence the requirement of monthly injection of palivizumab (<a href="./references#CD013757-bbs2-0026" title="BaxterD . Active and passive immunity, vaccine types, excipients and licensing. Occupational Medicine2007;57(8):552-6.">Baxter 2007</a>; <a href="./references#CD013757-bbs2-0099" title="SotoJA , GálvezNM , PachecoGA , BuenoSM , KalergisAM . Antibody development for preventing the human respiratory syncytial virus pathology. Molecular Medicine2020;26(1):35.">Soto 2020</a>). </p> <p>Candidates for immunoprophylaxis with palivizumab have changed over the past 22 years, depending on countries' public health policy. Since 2014, the American Academy of Pediatrics Guidelines indications have become more restrictive (<a href="./references#CD013757-bbs2-0029" title="BradyMT ,  Byington CL, DaviesHD , EdwardsKM , JacksonMA ,  Maldonado YA, et al, on behalf of American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics2014;134(2):415-20.">Brady 2014</a>), with results still inconclusive regarding guidelines impact, however, with a worrying trend towards an increase in the number of RSV‐related hospitalisations (<a href="./references#CD013757-bbs2-0031" title="CapizziA , SilvestriM , OrsiA , CutreraR , RossiGA , SaccoO . The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence. Italian Journal of Pediatrics2017;43(1):71.">Capizzi 2017</a>; <a href="./references#CD013757-bbs2-0048" title="GoldsteinM , KrilovLR , FergieJ , McLaurinKK , WadeSW , DiakunD , et al. Respiratory syncytial virus hospitalizations among U.S. preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016. American Journal of Perinatology2018;35(14):1433-42. [PMID: 29920638]">Goldstein 2018</a>; <a href="./references#CD013757-bbs2-0062" title="KrilovLR , FergieJ , GoldsteinM , BrannmanL . Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the rate, severity, and cost of respiratory syncytial virus hospitalizations among preterm infants. American Journal of Perinatology2020;37(2):174-83. [PMID: 31430818]">Krilov 2020</a>; <a href="./references#CD013757-bbs2-0114" title="ZemblesTN , BusheeGM , WilloughbyRE . Impact of American Academy of Pediatrics palivizumab guidance for children ≥ 29 and &lt; 35 weeks of gestational age. Journal of Pediatrics2019;209:125-9.">Zembles 2019</a>). Nevertheless, at least 30% of individuals who receive palivizumab do not fit these recommendations, probably because palivizumab is the only available pharmacological prevention strategy against RSV (<a href="./references#CD013757-bbs2-0107" title="TristS , HorsleyE , KatfH , TaskerN , MostaghimM . Improving the prescribing of palivizumab. Journal of Paediatrics and Child Health2018;54(12):1353-6.">Trist 2018</a>). </p> <p>Since its first use, palivizumab has proved to be effective in several clinical trials in different settings (<a href="./references#CD013757-bbs2-0022" title="AndersonEJ , Carosone-LinkP , YogevR , YiJ , SimõesEA . Effectiveness of palivizumab in high-risk infants and children: a propensity score weighted regression analysis. Pediatric Infectious Disease Journal2017;36(8):699-704.">Anderson 2017</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0074" title="MooreHC , deKlerkN , RichmondPC , FathimaP , XuR , KeilAD . Effectiveness of palivizumab against respiratory syncytial virus: cohort and case series analysis. Journal of Pediatrics2019;214:121-7.e1.">Moore 2019</a>). In a Cochrane Review from 2013, a significant effect was seen for palivizumab in preventing hospitalisations when compared to placebo (risk ratio  0.49, 95% CI 0.37 to 0.64) (<a href="./references#CD013757-bbs2-0021" title="AndabakaT , NickersonJW , Rojas-ReyesMX , RuedaJD , Bacic VrcaV , BarsicB . Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database of Systematic Reviews2013, Issue 4. Art. No: CD006602. [DOI: 10.1002/14651858.CD006602.pub4]">Andabaka 2013</a>). However, the cost of the medication remains high at USD 1416 per 100 mg. This is an important obstacle for its use, particularly in LMIC. This has led to a cost‐effectiveness analysis in different countries, settings, and conditions (<a href="./references#CD013757-bbs2-0021" title="AndabakaT , NickersonJW , Rojas-ReyesMX , RuedaJD , Bacic VrcaV , BarsicB . Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database of Systematic Reviews2013, Issue 4. Art. No: CD006602. [DOI: 10.1002/14651858.CD006602.pub4]">Andabaka 2013</a>). Although it has been proven cost‐effective in some countries (<a href="./references#CD013757-bbs2-0067" title="MacS , SumnerA , Duchesne-BelangerS , StirlingR , TunisM , SanderB . Cost-effectiveness of palivizumab for respiratory syncytial virus: a systematic review. Pediatrics2019;143(5):e20184064.">Mac 2019</a>; <a href="./references#CD013757-bbs2-0091" title="SchmidtR , MajerI , García RománN , Rivas BasterraA , GrubbE , Medrano LópezC . Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain. Health Economics Review2017;7(1):47.">Schmidt 2017</a>), studies in Israel and Germany tend to disagree affirming that a substantial decrease in the cost (36.8% to 83.3%) is needed in order to be a cost‐effective strategy amongst vulnerable populations (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0047" title="GinsbergGM , SomekhE , SchlesingerY . Should we use palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis. Israel Journal of Health Policy Research2018;7(1):1-14.">Ginsberg 2018</a>). As a consequence of its high economic burden, different studies have assessed whether a shorter course of palivizumab would provide the same efficacy and same RSV antibody levels than the regular five doses with inconclusive results (<a href="./references#CD013757-bbs2-0035" title="ClaydonJ , SurA , CallejasA , MihokoL , EddieK , RichardT , et al. Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen. PLOS ONE2017;12(4):e0176152.">Claydon 2017</a>; <a href="./references#CD013757-bbs2-0036" title="ClaydonJ , PopescuCR , ShaibaL , ChristophersonC , HumanD , TaylorR , et al. Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis. CMAJ Open2019;7(1):E88-93.">Claydon 2019</a>; <a href="./references#CD013757-bbs2-0063" title="La ViaWV , NotarioGF , YuXQ , SharmaS , NoertersheuserPA , RobbieGJ . Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulmonary Pharmacology and Therapeutics2013;26(6):666-71.">La Via 2013</a>; <a href="./references#CD013757-bbs2-0074" title="MooreHC , deKlerkN , RichmondPC , FathimaP , XuR , KeilAD . Effectiveness of palivizumab against respiratory syncytial virus: cohort and case series analysis. Journal of Pediatrics2019;214:121-7.e1.">Moore 2019</a>; <a href="./references#CD013757-bbs2-0085" title="RobbieGJ , ZhaoL , MondickJ , LosonskyG , RoskosLK . Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrobial Agents and Chemotherapy2012;56(9):4927-36.">Robbie 2012</a>). </p> <p>Other pharmacologic strategies have been assessed since RSV was first identified in 1956, and several are now under investigation and development (<a href="./references#CD013757-bbs2-0071" title="MejiasA , Ramilo O​​​​. New options in the treatment of respiratory syncytial virus disease. Journal of Infection2015;71(Suppl 1):S80-7.">Mejias 2015</a>; <a href="./references#CD013757-bbs2-0096" title="SimõesEA , BontL , ManzoniP , FaurouxB , PaesB , Figueras-AloyJ , et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infectious Diseases and Therapy2018;7(1):87-120.">Simões 2018</a>; <a href="./references#CD013757-bbs2-0106" title="TrippRA , PowerUF , OpenshawPJ , KauvarLM . Respiratory syncytial virus: targeting the G protein provides a new approach for an old problem. Journal of Virology2017;92(3):e01302-17.">Tripp 2017</a>). Palivizumab was also tested as an intravenous infusion during an acute RSV episode, but showed no benefit (<a href="./references#CD013757-bbs2-0019" title="AlansariK , ToaimahFH , AlmatarDH , El TatawyLA , DavidsonBL , QusadM . Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial. Pediatrics2019;143(3):e20182308. [DOI: 10.1542/peds.2018-2308]">Alansari 2019</a>), nor did RSV immunoglobulin (<a href="./references#CD013757-bbs2-0087" title="SandersSL , AgwanS , HassanM , vanDrielML , Del MarCB . Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. Cochrane Database of Systematic Reviews2019, Issue 8. Art. No: CD009417. [DOI: 10.1002/14651858.CD009417.pub2]">Sanders 2019</a>). In 2008, motavizumab, a mAb also used against RSV F glycoprotein, but with a 70‐fold increase in affinity compared to palivizumab was tested for preventing RSV LRTI (<a href="./references#CD013757-bbs2-0044" title="FernándezP , TrenholmeA , AbarcaK , GriffinMP , HultquistM , HarrisB , et al, on behalf of Motavizumab Study Group. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatrics2010;10:38.">Fernández 2010</a>). Although it proved to be more efficient than palivizumab in preventing RSV hospitalisations, it was not approved by the FDA due to dermatological side effects (<a href="./references#CD013757-bbs2-0032" title="Carbonell-EstranyX , SimõesEA , DaganR , HallCB , HarrisB ,  Hultquist M, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics2010;125(1):e35-51.">Carbonell‐Estrany 2010</a>). Other mAbs under investigation include human IgA antibody formats of palivizumab and motavizumab (<a href="./references#CD013757-bbs2-0060" title="JacobinoSR , NederendM , ReijneveldJF , AugustijnD , JansenJH , MeeldijkJ , et al. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. mAbs2018;10(3):453-62.">Jacobino 2018</a>), anti RSV G glycoprotein or N‐protein (<a href="./references#CD013757-bbs2-0106" title="TrippRA , PowerUF , OpenshawPJ , KauvarLM . Respiratory syncytial virus: targeting the G protein provides a new approach for an old problem. Journal of Virology2017;92(3):e01302-17.">Tripp 2017</a>) and mAbs with a longer half‐life (<a href="./references#CD013757-bbs2-0050" title="GriffinMP , YuanY , TakasT , DomachowskeJB , MadhiSA , ManzoniP , et al. Single-dose nirsevimab for prevention of RSV in preterm infants. New England Journal of Medicine2020;383(5):415-25. [DOI: 10.1056/NEJMoa1913556]">Griffin 2020</a>; <a href="./references#CD013757-bbs2-0116" title="ZhuQ , McLellanJS , KallewaardNL , UlbrandtND , PalaszynskiS , ZhangJ , et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Science Translational Medicine2017;9(388):1-12.">Zhu 2017</a>).  </p> </section> <section id="CD013757-sec-0012"> <h3 class="title" id="CD013757-sec-0012">How the intervention might work</h3> <p>Palivizumab is a humanised monoclonal immunoglobulin G1, directed against an epitope of RSV surface glycoprotein F (<a href="./references#CD013757-bbs2-0061" title="JohnsonS , OliverC , PrinceGA , HemmingVG , PfarrDS ,  WangSC , et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. Journal of Infectious Diseases1997;176(5):1215-24.">Johnson 1997</a>). When binding to it, palivizumab prevents the fusion of the viral particle and host cell membrane (avoiding the entry of the viral genome used for replication and transcription) and might also suppress the syncytia formation in respiratory epithelial cells (<a href="./references#CD013757-bbs2-0099" title="SotoJA , GálvezNM , PachecoGA , BuenoSM , KalergisAM . Antibody development for preventing the human respiratory syncytial virus pathology. Molecular Medicine2020;26(1):35.">Soto 2020</a>; <a href="./references#CD013757-bbs2-0113" title="YoungJ . Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respiratory Medicine2002;96(Suppl 2):S31-5.">Young 2002</a>). In addition, palivizumab diminishes viral activity and cell‐to‐cell transmission, reducing RSV virulence and its risk of developing RSV LRTI (<a href="./references#CD013757-bbs2-0037" title="CollinsPL , MeleroJA . Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Research2011;162(1-2):80-99.">Collins 2011</a>). </p> </section> <section id="CD013757-sec-0013"> <h3 class="title" id="CD013757-sec-0013">Why it is important to do this review</h3> <p>In 2013, a Cochrane Review assessed the role of palivizumab in preventing RSV LRTI (<a href="./references#CD013757-bbs2-0021" title="AndabakaT , NickersonJW , Rojas-ReyesMX , RuedaJD , Bacic VrcaV , BarsicB . Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database of Systematic Reviews2013, Issue 4. Art. No: CD006602. [DOI: 10.1002/14651858.CD006602.pub4]">Andabaka 2013</a>). Since then, many trials have continued evaluating its effectiveness and defining its usefulness in different subpopulations.  A non‐Cochrane systematic review on the topic was published in 2014 with methodological limitations (<a href="./references#CD013757-bbs2-0109" title="WegzynC , TohL , NotarioG , BiguenetS , UnnebrinkK , ParkC , et al. Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review. Infectious Diseases and Therapy2014;3(2):133-58.">Wegzyn 2014</a>), such as the lack of risk of bias assessment. Given the high cost of the drug, it is essential to know if palivizumab continues to be effective in preventing severe RSV disease in high‐risk children. Meanwhile, the proportion of RSV infections continues to rise, especially in LMIC; despite the probable changing landscape regarding RSV interventions, palivizumab continues to be the only approved RSV‐related drug. Our main goal is to provide a high‐quality review of the evidence on the effects of palivizumab in preventing severe RSV infection in children.  </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013757-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013757-sec-0014"></div> <p>To assess the effects of palivizumab for preventing severe respiratory syncytial virus infection in children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013757-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013757-sec-0015"></div> <section id="CD013757-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013757-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs), including cluster‐RCTs. We did not include cross‐over RCTs as they are not relevant to the review question. We included studies reported as full text, those published as abstract only, and unpublished data where it was possible to establish eligibility for inclusion when data were limited. There were no language or publication restrictions.  </p> </section> <section id="CD013757-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included children (0 to 24 months of age) of both genders, regardless of RSV infection history. We included children with immunodeficiency disorders. We excluded children with cystic fibrosis, as a related Cochrane Review has already been published on that topic (<a href="./references#CD013757-bbs2-0086" title="RobinsonKA , OdelolaOA , SaldanhaIJ . Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database of Systematic Reviews2016, Issue 7. Art. No: CD007743. [DOI: 10.1002/14651858.CD007743.pub6]">Robinson 2016</a>).  </p> </section> <section id="CD013757-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing palivizumab given intramuscularly or intravenously at a dose of 15 mg/kg once a month (maximum five doses) with placebo, no intervention or standard care alone (oxygen supplementation, bronchodilators, corticosteroids, intravenous fluids, etc). We included co‐interventions (e.g. corticosteroids) provided they were not part of the randomised treatment and were consistent across groups.  </p> </section> <section id="CD013757-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>The outcomes listed here were not eligibility criteria for this review but were outcomes of interest within the included studies.  </p> <section id="CD013757-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013757-list-0001"> <li> <p>Hospitalisation due to RSV infection: defined as the number of children hospitalised with laboratory‐confirmed infection. </p> </li> <li> <p>Mortality: death due to all causes. We also reported the cause of deaths for each group (including deaths related to RSV infection). </p> </li> <li> <p>Adverse events: defined as any unexpected or harmful occurrence in the participant, such as rash, pain in the injection site, fever, nausea, vomiting, diarrhoea, etc., reported in absolute numbers or proportions. We intended to report non‐serious and serious adverse events (including death, disability, life‐threatening events or those requiring hospitalisations) separately. Had there been multiple events reported within one participant, we would have reported this separately. </p> </li> </ol> </p> </section> <section id="CD013757-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013757-list-0002"> <li> <p>Hospitalisation due to respiratory‐related illness: defined as the number of children needing admission to hospital for treatment of respiratory symptoms without alternative aetiology and with negative RSV antigen test or no test done. </p> </li> <li> <p>Length of hospital stay: number of days in which a child has been hospitalised due to RSV infection or respiratory‐related illness. </p> </li> <li> <p>RSV infection: incidence of laboratory‐confirmed RSV‐bronchiolitis.</p> </li> <li> <p>Number of wheezing days: wheeze or bronchodilator medication use reported by parents.</p> </li> <li> <p>Days of supplemental oxygen.</p> </li> <li> <p>Intensive care unit length of stay.</p> </li> <li> <p>Mechanical ventilation days.</p> </li> </ol> </p> <p>For continuous outcomes only available in a subset of participants (length of hospital stay, number of wheezing days, days of supplemental oxygen, ICU length of stay, mechanical ventilation days) we presented the data as days per 100 randomised children following the guidance in Section 6.9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013757-bbs2-0056" title="HigginsJP ,  SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane 2019. Available from www.training.cochrane.org/handbook/archive/v6.">Higgins 2019a</a>). </p> <section id="CD013757-sec-0023"> <h6 class="title">Timing of outcome measurement</h6> <p>We considered outcomes measured up to and including 12 months after randomisation as short term and more than 12 months as long term. When multiple results were reported for each outcome, we included the longest follow‐up in each category. </p> </section> </section> </section> </section> <section id="CD013757-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013757-sec-0025"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from the inception of each database to the date of search with no restrictions on the language of publication or publication status: </p> <p> <ol id="CD013757-list-0003"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) (2021, Issue 10) searched 14 October 2021; </p> </li> <li> <p>MEDLINE (Ovid) from 1946 to 14 October 2021;</p> </li> <li> <p>Embase (Elsevier.com) from 1947 to 15 October 2020;</p> </li> <li> <p>Latin American and Caribbean Health Science Information database (LILACS) (BIREME) from 1982 to 14 October 2021; </p> </li> <li> <p>CINAHL (Cumulative Index to Nursing and Allied Health Literature) from 1981 to 14 October 2021; and </p> </li> <li> <p>Scopus from 1970 to 14 October 2021.</p> </li> </ol> </p> <p>For detailed search strategies, see <a href="./appendices#CD013757-sec-0081">Appendix 1</a>.  </p> </section> <section id="CD013757-sec-0026"> <h4 class="title">Searching other resources</h4> <p>We attempted to identify other potentially eligible studies or ancillary publications by searching the reference list of included studies, systematic reviews, meta‐analyses, and health technology assessment reports. We contacted experts in the field to identify additional unpublished materials. We searched the websites of relevant manufacturers for information on trials. We sought errata or retractions of the included studies. We contacted authors of the included studies to identify other unpublished studies. We searched for registered and ongoing trials in the following trial registers:  </p> <p> <ol id="CD013757-list-0004"> <li> <p>ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) searched 14 October 2021; and </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch/</a>) searched 14 October 2021. </p> </li> </ol> </p> <p>For detailed search strategies, see <a href="./appendices#CD013757-sec-0081">Appendix 1</a>.  </p> </section> </section> <section id="CD013757-sec-0027"> <h3 class="title" id="CD013757-sec-0027">Data collection and analysis</h3> <section id="CD013757-sec-0028"> <h4 class="title">Selection of studies</h4> <p>We used Cochrane’s Screen4Me workflow to help assess the search results. Screen4Me comprises three components: known assessments – a service that matches records in the search results to records that have already been screened in Cochrane Crowd and been labelled as an RCT or as Not an RCT; the RCT classifier – a machine learning model that distinguishes RCTs from non‐RCTs, and if appropriate, Cochrane Crowd – Cochrane’s citizen science platform where the Crowd help to identify and describe health evidence. For more information about Screen4Me and the evaluations that have been done, visit the Screen4Me webpage on the Cochrane Information Specialist’s portal: https://community.cochrane.org/organizational‐info/resources/resources‐ groups/information‐specialists‐portal. More detailed information regarding evaluations of the Screen4Me components can also be found in the following publications: <a href="./references#CD013757-bbs2-0070" title="MarshallIJ , Noel-StorrA , KuiperJ , ThomasJ , WallaceBC . Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide. Research Synthesis Methods2018;9:602-14.">Marshall 2018</a>; <a href="./references#CD013757-bbs2-0079" title="Noel-StorrAH , DooleyG , WisniewskiS , GlanvilleJ , ThomasJ , CoxS , et al. Cochrane Centralised Search Service showed high sensitivity identifying randomized controlled trials: a retrospective analysis. Journal of Clinical Epidemiology2020;127:142-50.">Noel‐Storr 2020</a>; <a href="./references#CD013757-bbs2-0080" title="Noel-StorrA , DooleyG , ElliottJ , SteeleE , ShemiltI , MavergamesC , et al. An evaluation of Cochrane Crowd found that crowdsourcing produced accurate results in identifying randomized trials. Journal of Clinical Epidemiology 2021 Jan 18 [Epub ahead of print]. [DOI: 10.1016/j.jclinepi.2021.01.006]">Noel‐Storr 2021</a>;<a href="./references#CD013757-bbs2-0103" title="ThomasJ , McDonaldS , Noel-StorrA , ShemiltI , ElliottJ , MavergamesC , et al. Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane Reviews. Journal of Clinical Epidemiology 2020 Nov 7 [Epub ahead of print]. [DOI: 10.1016/j.jclinepi.2020.11.003]">Thomas 2020</a>. </p> <p>Two review authors (LG, LS) independently screened the titles and abstracts of studies we identified as a result of the search for potential inclusion in the review. </p> <p>We retrieved the full‐text study reports/publications deemed potentially eligible, and two review authors (LG, LS) independently screened the full texts and identified studies for inclusion and identified and recorded reasons for exclusion of the ineligible studies. Any disagreements were resolved through discussion or by consulting a third review author (JVAF) when required. We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and <a href="./references#CD013757-sec-0105" title="">Characteristics of excluded studies</a> table (<a href="./references#CD013757-bbs2-0073" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Version 2. PLOS Medicine2009;339:b2535.">Moher 2009</a>). We used Covidence software for study selection (<a href="./references#CD013757-bbs2-0038" title="Covidence. Version accessed 5 May 2020. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>). We did not impose any language restrictions. </p> </section> <section id="CD013757-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data that had been piloted on at least one study in the review. One review author (LG or LS) extracted study characteristics from the included studies. We extracted the following study characteristics. </p> <p> <ol id="CD013757-list-0005"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and location, study setting, withdrawals, and date of study. </p> </li> <li> <p>Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, RSV infection history, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>Two review authors (LG, LS) independently extracted outcome data from included studies. We noted in the <a href="./references#CD013757-sec-0104" title="">Characteristics of included studies</a> table if outcome data were not reported in a useable way. Any disagreements were resolved by consensus or by involving a third review author (JVAF). One review author (LG) transferred data into Review Manager 5 software (<a href="./references#CD013757-bbs2-0084" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). A second review author (JVAF) double‐checked that data had been entered correctly by comparing the data presented in the systematic review with the study reports. The second review author (JVAF) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD013757-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (LG, LS) independently assessed risk of bias of the results of the main outcomes (those included in the <a href="./full#CD013757-tbl-0001">summary of findings Table 1</a>, see below) in each study using a recently developed revision of the Cochrane risk of bias tool (RoB 2: a revised tool to assess the risk of bias in randomised trials) (<a href="./references#CD013757-bbs2-0056" title="HigginsJP ,  SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane 2019. Available from www.training.cochrane.org/handbook/archive/v6.">Higgins 2019a</a>; <a href="./references#CD013757-bbs2-0101" title="SterneJA , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>). Any disagreements were resolved by discussion or by involving another review author (JVAF). We assessed risk of bias according to the following domains. </p> <p> <ol id="CD013757-list-0006"> <li> <p>The randomisation process.</p> </li> <li> <p>Deviations from intended interventions.</p> </li> <li> <p>Missing outcome data.</p> </li> <li> <p>Measurement of the outcome.</p> </li> <li> <p>Selection of the reported results.</p> </li> </ol> </p> <p>Answers to signalling questions and supporting information collectively led to a domain‐level judgement in the form of 'low risk', 'some concerns', or 'high risk' of bias. These domain‐level judgements informed an overall risk of bias judgement for the outcome. We considered the algorithm proposed judgements and provided a quote from the study report together with a justification for our judgement in the risk of bias table. We also provided reasons for judgments that did not follow the algorithm. We summarised the  risk of bias judgements across different studies for each of the domains listed. When judging the bias due to deviations from intended interventions, we focused the analyses on the effect of assignment to intervention (<a href="./references#CD013757-bbs2-0056" title="HigginsJP ,  SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane 2019. Available from www.training.cochrane.org/handbook/archive/v6.">Higgins 2019a</a>). We aimed to source published protocols for the assessment of selective reporting. Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the risk of bias table. </p> <p>We used the 22 August 2019 version of the RoB 2 Excel tool to manage the data supporting the answers to the signalling questions and risk of bias judgements (available at <a href="https://www.riskofbias.info/" target="_blank">https://www.riskofbias.info/</a>). All these data are publicly available as supplementary material in the Open Science Framework platform (<a href="https://osf.io/" target="_blank">osf.io/</a>). </p> <p>For cluster‐RCTs, we would have used the RoB 2 tool and added an additional domain specific to cluster RCTs from the archived version of the tool (Domain 1b ‐ ‘Bias arising from the timing of identification and recruitment of participants’; see <a href="https://www.riskofbias.info/" target="_blank">https://www.riskofbias.info/</a>) with its corresponding signalling questions, following the guidance in Section 23.1.2 and Table 23.1.a of the Cochrane Handbook (<a href="./references#CD013757-bbs2-0058" title="HigginsJP , EldridgeS , LiT . Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook/archive/v6.">Higgins 2019c</a>). </p> <p>We made summary assessments of the risk of bias for each short‐ and long‐term result for each outcome (across domains) within and across studies (<a href="./references#CD013757-bbs2-0056" title="HigginsJP ,  SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane 2019. Available from www.training.cochrane.org/handbook/archive/v6.">Higgins 2019a</a>). </p> <section id="CD013757-sec-0031"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol and reported any deviations from it in the <a href="#CD013757-sec-0096">Differences between protocol and review</a> section of the systematic review. </p> </section> </section> <section id="CD013757-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We entered the outcome data for each study into data tables in Review Manager 5 to calculate the treatment effects (<a href="./references#CD013757-bbs2-0084" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>).   </p> <p>We analysed dichotomous data as risk ratios (RRs) and continuous data as mean difference (MD). We reported corresponding 95% confidence intervals (CIs). We entered data presented as a scale with a consistent direction of effect. </p> <p>We undertook meta‐analyses only where this was meaningful, that is if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense. </p> </section> <section id="CD013757-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>Where multiple trial arms were reported in a single trial, we included only the treatment arms relevant to the review topic. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were combined in the same study, we would have followed the guidance in Section 6.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to avoid double‐counting (<a href="./references#CD013757-bbs2-0057" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook/archive/v6.">Higgins 2019b</a>). Our preferred approach would have been to combine groups to create a single pair‐wise comparison. For cluster‐RCTs, we would have considered the cluster as the unit of analysis, not the individual participant, in order to avoid unit of analysis errors, as stated in Section 23.1.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013757-bbs2-0057" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook/archive/v6.">Higgins 2019b</a>) </p> </section> <section id="CD013757-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data where possible (e.g. when a study was identified as abstract only). </p> <p>If numerical outcome data such as standard deviations or correlation coefficients were missing, and they could not be obtained from the authors, we calculated them from other available statistics such as P values according to the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013757-bbs2-0057" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook/archive/v6.">Higgins 2019b</a>). </p> </section> <section id="CD013757-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity amongst the trials in each analysis. If we identified substantial heterogeneity, we reported it and explored possible causes by prespecified subgroup analysis.  </p> <p>We used the rough guide to interpretation as outlined in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions </i>(<a href="./references#CD013757-bbs2-0057" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook/archive/v6.">Higgins 2019b</a>), as follows: </p> <p> <ol id="CD013757-list-0007"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity; and</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ol> </p> <p>We avoided the use of absolute cut‐off values but interpreted I² in relation to the size and direction of effects and strength of evidence for heterogeneity. We performed a random‐effects meta‐analysis, which accounts for between‐study heterogeneity. </p> </section> <section id="CD013757-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>If there were more than 10 trials, we would create and examin a funnel plot to explore possible small‐study and publication biases. If searches identified trial protocols, clinical trial registrations or abstracts indicating the existence of unpublished studies, we attempted to determine the status of any unpublished studies through contact with the investigators. </p> <p>We considered outcome reporting bias in our risk of bias assessments.</p> </section> <section id="CD013757-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We pooled data from studies judged to be clinically homogeneous using Review Manager 5 software (<a href="./references#CD013757-bbs2-0084" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). If more than one study provided useable data in any single comparison, we performed a meta‐analysis. We used a random‐effects model, as this is usually a more conservative approach. We included all studies in the primary analysis and planned to explore the effect of bias in a sensitivity analysis (see <a href="#CD013757-sec-0039">Sensitivity analysis</a>). </p> </section> <section id="CD013757-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses.</p> <p> <ol id="CD013757-list-0008"> <li> <p>High‐risk children (e.g. children with heart disease, respiratory diseases, premature children, children with low birth weight) versus average‐risk children. </p> </li> <li> <p>Tropical regions versus non‐tropical regions.</p> </li> <li> <p>High‐income countries versus low‐ and middle‐income countries</p> </li> </ol> </p> <p>We were only able to carry out the subgroup analysis for high‐income countries versus low‐ and middle‐income countries, and only for the outcome hospitalisation due to respiratory‐related illness. </p> <p>We used the Chi² test to test for subgroup interactions in Review Manager 5 (<a href="./references#CD013757-bbs2-0084" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD013757-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to carry out the following sensitivity analyses:</p> <p> <ol id="CD013757-list-0009"> <li> <p>Repeated the analysis excluding unpublished studies (if there were any).</p> </li> <li> <p>Repeated the analysis excluding studies at an overall high risk of bias.</p> </li> <li> <p>Repeated the analysis excluding small studies (if there were any).</p> </li> </ol> </p> <p>However, no studies fitted the criteria. </p> </section> <section id="CD013757-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created <a href="./full#CD013757-tbl-0001">summary of findings Table 1</a> using the following outcomes: </p> <p> <ol id="CD013757-list-0010"> <li> <p>hospitalisation due to RSV infection (long term);</p> </li> <li> <p>mortality (long term);</p> </li> <li> <p>adverse events (non‐serious/serious: long term);</p> </li> <li> <p>hospitalisation due to respiratory‐related illness (long term);</p> </li> <li> <p>RSV infection (long‐term); and</p> </li> <li> <p>number of wheezing days (three to six years).</p> </li> </ol> </p> <p>Two review authors (LG, LS) used the five GRADE considerations (overall RoB 2 judgement, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of a body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD013757-bbs2-0025" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490-4.">Atkins 2004</a>). We used the methods and recommendations described in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013757-bbs2-0057" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook/archive/v6.">Higgins 2019b</a>) emplying GRADEproGDT software (<a href="./references#CD013757-bbs2-0049" title="GRADEpro GDT. Version accessed 13 October 2021. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). Any disagreements were resolved by discussion or by involving another review author (JVAF). We assessed evidence certainty according to the GRADE criteria. We considered RCTs as high certainty evidence if the five factors above related to risk if bias (see <a href="#CD013757-sec-0030">Assessment of risk of bias in included studies</a>) were not present to any serious degree, but downgraded the certainty to moderate, low or very low as needed. We downgraded the certainty of the evidence once if a GRADE consideration was serious, and twice if very serious. We justified all decisions to down‐ or upgrade the certainty of the evidence using footnotes, and made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013757-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013757-sec-0041"></div> <section id="CD013757-sec-0042"> <h3 class="title">Description of studies</h3> <p>For study details, see <a href="./references#CD013757-sec-0104" title="">Characteristics of included studies</a>; <a href="./references#CD013757-sec-0105" title="">Characteristics of excluded studies</a>; <a href="./references#CD013757-sec-0106" title="">Characteristics of studies awaiting classification</a>.  </p> <section id="CD013757-sec-0043"> <h4 class="title">Results of the search</h4> <p>For a detailed description of our screening process, see the study flow diagram (<a href="#CD013757-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013757-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram " data-id="CD013757-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram </p> </div> </div> </div> <p>The searches of the databases identified a total of 5046 search results of which 2787 records remained after deduplication. In assessing the studies, we used Cochrane’s Screen4Me workflow to help identify potential reports of randomised trials. The results of the Screen4Me assessment process are provided in <a href="#CD013757-fig-0002">Figure 2</a>. We then assessed the remaining 142 records left after Screen4Me. Our searches of the trial registers identified a further 43 studies. Our screening of the reference lists of the included publications did not reveal any additional RCTs. We therefore had a total of 185 records of which 158 records were excluded based on title and abstract. We obtained the full texts of the remaining 27 records. We excluded 11 studies (see <a href="./references#CD013757-sec-0105" title="">Characteristics of excluded studies</a>). We added two records to <a href="./references#CD013757-sec-0106" title="">Characteristics of studies awaiting classification</a>. We did not identify any ongoing studies. </p> <div class="figure" id="CD013757-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Screen4Me summary diagram" data-id="CD013757-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Screen4Me summary diagram</p> </div> </div> </div> <p>We finally included five studies reported in 14 references.</p> </section> <section id="CD013757-sec-0044"> <h4 class="title">Included studies</h4> <p>We included five studies with a total 3343 participants (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>; <a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>). </p> <section id="CD013757-sec-0045"> <h5 class="title">Designs</h5> <p>All studies were parallel RCTs (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>; <a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>).  </p> </section> <section id="CD013757-sec-0046"> <h5 class="title">Sample sizes</h5> <p>The median sample size was 429 participants (interquartile range 83 to 1287). The largest sample size was 1502 participants (<a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>) and the smallest was 42 participants (<a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>).  </p> </section> <section id="CD013757-sec-0047"> <h5 class="title">Settings</h5> <p>All studies were conducted in an outpatient setting (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>; <a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>). One study also included neonatal ICU hospitalised infants (<a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>). </p> <p>Four of the included studies were multicentre studies (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>). Two of these studies were also multinational studies (<a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>), conducted in the United States, Canada, Sweden, Germany, Poland, France and the United Kingdom. The other two multicentre studies were conducted in the United States, <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>, and the Netherlands, <a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>. One study was a single‐centre study conducted in Turkey (<a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>). </p> <p>All studies were reported in the English language. </p> </section> <section id="CD013757-sec-0048"> <h5 class="title">Participants</h5> <p>Three studies included infants 24 months of age or younger at the start of the RSV season with a gestational age of 35 weeks or less (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>). One study included infants with a gestational age of 32 weeks or younger who were hospitalised in the neonatal ICU, infants 12 months of age or less at the beginning of the RSV season with a gestational age of 28 weeks, and infants born at 29 to 32 weeks of gestational age who were younger than six months old at the beginning of RSV season (<a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>). Two studies included children who had bronchopulmonary dysplasia (BPD) and were 24 months of age or younger (<a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>).  Finally, one study included children 24 months old or younger at the time of randomisation with documented haemodynamically significant congenital heart disease (CHD) determined by the investigator and had unoperated or partially corrected CHD (<a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>).  </p> </section> <section id="CD013757-sec-0049"> <h5 class="title">Interventions</h5> <p>In all of the included trials, palivizumab was delivered intramuscularly, except for one study in which it was delivered intravenously (<a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>).  All studies delivered 15 mg/kg doses. One study was a dose‐escalation study, testing three different doses (<a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>); only data for the recommended approved dose of 15 mg/kg were included in our analyses. Four studies compared palivizumab against placebo (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>), and one study compared palivizumab versus no intervention (<a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>).  </p> </section> <section id="CD013757-sec-0050"> <h5 class="title">Outcomes</h5> <p>All studies reported the effect of the intervention on hospitalisation due to RSV infection, all‐cause mortality, and hospitalisations due to respiratory‐related illness. Three studies reported adverse events (<a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>). Three studies reported RSV infection (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>; <a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>). Two studies reported length of hospital stay, days of supplemental oxygen, intensive care unit length of stay, and mechanical ventilation days (<a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>). One study reported the number of wheezing days (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>).  </p> </section> <section id="CD013757-sec-0051"> <h5 class="title">Funding sources</h5> <p>Most studies (four of five studies, 80%) did not specify their funding sources. <a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a> was funded by Abbott Laboratories (Abbott International PLC (UK)) and the Netherlands Organisation for Health Research and Development, with no restrictions for publication of the research data.  </p> </section> </section> <section id="CD013757-sec-0052"> <h4 class="title">Excluded studies</h4> <p>We excluded 11 reports after full‐text assessment. One report compared palivizumab against motavizumab (<a href="./references#CD013757-bbs2-0009" title="EUCTR2007-002070-61-PL. A study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of MEDI-524, a humanized enhanced potency monoclonal antibody against respiratory syncytial virus (RSV), in children with hemodynamically significant congenital heart disease. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-002070-61-PL (first received 10 August 2007). ">EUCTR2007‐002070‐61‐PL</a>). Two reports were informative summaries with no authors declared and no original research data reported (<a href="./references#CD013757-bbs2-0006" title="Prevention of respiratory syncytial virus infection by monoclonal antibody. Deutsche Apotheker Zeitung1999;139(28):36. ">Anonymous 1999</a>; <a href="./references#CD013757-bbs2-0007" title="Palivizumab: new indication. Moderate reduction in hospitalisation rate. Prescrire International2004;13(74):213-6. ">Anonymous 2004</a>). One report was a narrative review (<a href="./references#CD013757-bbs2-0008" title="DriverLC , OertelMD . Synagis: an anti-RSV monoclonal antibody. Pediatric Nursing1999;25(5):527-30. ">Driver 1999</a>). Another report was an evidence synopsis (<a href="./references#CD013757-bbs2-0010" title="IgnacioL , AlfalehK . Does RSV prophylaxis prevents future recurrent wheeze in preterm infants?Journal of Clinical Neonatology2013;2(3):116-8. ">Ignacio 2013</a>). The remaining six reports were observational studies (<a href="./references#CD013757-bbs2-0011" title="JohnsonKE , WeismanLE . Palivizumab (Synagis®) in the prevention of lower respiratory tract infection in children due to respiratory syncytial virus (RSV). Today's Therapeutic Trends1999;17(3):227-42. ">Johnson 1999</a>; <a href="./references#CD013757-bbs2-0012" title="KoganesawaM , OnoT , TakamidoS , TakagiT , YamaokaD , UjiieG , et al. Prophylactic palivizumab prevents respiratory syncytial virus infection in pediatric patients with immunodeficiencies. Pediatric Blood &amp; Cancer2019;66:S39. ">Koganesawa 2019</a>; <a href="./references#CD013757-bbs2-0013" title="NaverL , ErikssonM , EwaldU , LindeA , LindrothM , SchollinJ . Prophylaxis against RS virus infection [Profylax mot rs-virusinfektion.]. Läkartidningen2002;99(3):170-1. ">Naver 2002</a>; <a href="./references#CD013757-bbs2-0014" title="PinI , PilenkoC , BostM . Prevention of infection by respiratory syncytial virus (VRS) by SYNAGYS® (PALIVIZUMAB). Allergie et Immunologie2002;34(10):371-4. ">Pin 2002</a>; <a href="./references#CD013757-bbs2-0015" title="RajakumarD , TanB , BodaniJ , ZhuT , JanzenB , Bodani R et al. Children hospitalized with respiratory syncytial virus (RSV) infection after palivizumab prophylaxis in two large paediatric tertiary care centers. Acta Paediatrica2009;98:214-5. ">Rajakumar 2009</a>; <a href="./references#CD013757-bbs2-0016" title="TullohR , FlandersL , HendersonJ , ThompsonR , FeltesT . Does RSV infection cause pulmonary hypertension in children undergoing cardiac surgery?Archives of Disease in Childhood2011;96:A37-8. ">Tulloh 2011</a>). </p> </section> </section> <section id="CD013757-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias assessments for each outcome, including all domain judgements and support for judgement, are provided in the risk of bias tables within the <a href="./references#CD013757-sec-0104" title="">Characteristics of included studies</a> section and at the side of all forest plots. To access the further detailed risk of bias assessment data, visit <a href="https://osf.io/26dns/" target="_blank">https://osf.io/26dns/</a> (DOI 10.17605/OSF.IO/26DNS). </p> <p>Risk of bias was similar across most outcomes, judged as 'low'. The only exception was outcomes reported by one study (<a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>) which were judged as 'some concerns'. This trial did not adequately describe allocation concealment and, unlike the other trials, it compared palivizumab to 'no intervention', which raised concerns due to deviations from intended interventions, as this was not adequately described. This study reported hospitalisations (due to respiratory illness and RSV infection), mortality and RSV infection. However, this did not affect our GRADE judgement for these results considering the trial's relative contribution to the overall estimate. </p> </section> <section id="CD013757-sec-0054"> <h3 class="title" id="CD013757-sec-0054">Effects of interventions</h3> <p>See: <a href="./full#CD013757-tbl-0001"><b>Summary of findings 1</b> Palivizumab compared to placebo, no intervention or standard care for preventing respiratory syncytial virus (RSV) infection in children</a> </p> <section id="CD013757-sec-0055"> <h4 class="title">1. Palivizumab versus placebo or no intervention</h4> <p>Five studies with a total of 3343 participants were included in this comparison (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>; <a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>). See <a href="./full#CD013757-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD013757-sec-0056"> <h5 class="title">Primary outcomes</h5> <section id="CD013757-sec-0057"> <h6 class="title">1.1. Hospitalisation due to RSV infection</h6> <p>Five studies with 3343 participants reported this outcome (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>; <a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>). Palivizumab reduces hospitalisation due to RSV infection compared to placebo or no intervention at two years' follow‐up (risk ratio (RR) 0.44, 95% confidence interval (CI) 0.30 to 0.64; I² = 23%; <a href="./references#CD013757-fig-0003" title="">Analysis 1.1</a>). We assessed the evidence for this outcome as of high certainty.  </p> </section> <section id="CD013757-sec-0058"> <h6 class="title">1.2 Mortality</h6> <p>Five studies with 3343 participants reported this outcome (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>; <a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>). Palivizumab probably results in little to no difference in mortality compared to placebo or no intervention at two years' follow‐up (RR 0.69, 95% CI 0.42 to 1.15; I² = 0%; <a href="./references#CD013757-fig-0004" title="">Analysis 1.2</a>). We assessed the evidence for this outcome as of moderate certainty due to concerns about imprecision.  </p> </section> <section id="CD013757-sec-0059"> <h6 class="title">1.3 Adverse events</h6> <p>Three studies with 2831 participants reported this outcome (<a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>). Palivizumab probably results in little to no difference in adverse events compared to placebo or no intervention at 150 days' follow‐up (RR 1.09, 95% CI 0.85 to 1.39; I² = 0%; <a href="./references#CD013757-fig-0005" title="">Analysis 1.3</a>). We assessed the evidence for this outcome as of moderate certainty due to concerns about imprecision.   </p> </section> </section> <section id="CD013757-sec-0060"> <h5 class="title">Secondary outcomes</h5> <section id="CD013757-sec-0061"> <h6 class="title">1.4 Hospitalisation due to respiratory‐related illness</h6> <p>Five studies with 3343 participants reported this outcome (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>; <a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>). Palivizumab probably results in a slight reduction in hospitalisation due to respiratory‐related illness compared to placebo or no intervention at two years' follow‐up (RR 0.78, 95% CI 0.62 to 0.97; I² = 45%; <a href="./references#CD013757-fig-0006" title="">Analysis 1.4</a>). We assessed the evidence for this outcome as of moderate certainty due to concerns about imprecision.  </p> </section> <section id="CD013757-sec-0062"> <h6 class="title">1.5 Subgroup analysis: hospitalisation due to respiratory‐related illness</h6> <p>We found that palivizumab results in a higher reduction in hospitalisation due to respiratory‐related illness in lower‐ middle‐ime countries (LMIC) (RR 0.47, 95% CI 0.18 to 1.22) compared to HIC (RR 0.80, 95% CI 0.65 to 0.99) (test for subgroup differences: P = 0.28, I² = 14.0%; <a href="./references#CD013757-fig-0007" title="">Analysis 1.5</a>).  </p> </section> <section id="CD013757-sec-0063"> <h6 class="title">1.6 Length of hospital stay</h6> <p>Two studies with 2789 participants reported this outcome (<a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>). Palivizumab may result in little to no difference in length of hospital stay compared to placebo or no intervention at 150 days' follow‐up (mean difference (MD) ‐42.24, 95% CI ‐84.77 to 0.29; I² = 64%; <a href="./references#CD013757-fig-0008" title="">Analysis 1.6</a>).  </p> </section> <section id="CD013757-sec-0064"> <h6 class="title">1.7 RSV infection</h6> <p>Three studies with 554 participants reported this outcome (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>; <a href="./references#CD013757-bbs2-0004" title="SubramanianK , WeismanL , RhodesT , AriagnoR , SanchezPJ , SteichenJ , et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatric Infectious Disease Journal1998;17(2):110-5. ">Subramanian 1998</a>; <a href="./references#CD013757-bbs2-0005" title="TavsuI , GursoyT , DirmanS , ErbilN , OvaliF . Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?American Journal of Perinatology2014;31(8):667-71. ">Tavsu 2014</a>). Palivizumab may result in a large reduction in RSV infection compared to placebo or no intervention at two years' follow‐up (RR 0.33, 95% CI 0.20 to 0.55; I² = 0%; <a href="./references#CD013757-fig-0009" title="">Analysis 1.7</a>). We assessed the evidence for this outcome as of low certainty due to serious concerns about imprecision.   </p> </section> <section id="CD013757-sec-0065"> <h6 class="title">1.8 Number of wheezing days</h6> <p>One study with 429 participants reported this outcome (<a href="./references#CD013757-bbs2-0001" title="BlankenM , RoversM , MolenaarJ , Winkler-SeinstraP , MeijerA , KimpenJ . Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 – 7; Washington, D.C. In: Pediatric Academic Societies Annual Meeting. 2013. BlankenM , RoversM , SandersE , BontL . Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials2012;33(6):1287-92. BlankenMO , FrederixGW , NibbelkeEE , Hendrik K,  KoffijbergH ,  Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. European Journal of Pediatrics2018;177(1):133-44. BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , KimpenJL ,  et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine2013;368(19):1791-9. BontL , BlankenMO , RoversMM , MolenaarJM , Winkler-SeinstraPL , MeijerA , et al. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life. American Journal of Respiratory and Critical Care Medicine2013;187:A6127. Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial. www.clinicaltrialsregister.eu/ctr-search/trial/2007-004105-10/NL (first received 2 June 2008). ManW ,  Scheltema N,  Van Houten M,  NibbelkeE ,  AchtenN ,  Arp K, et al. Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years. European Respiratory Journal2019;54:OA4939. ManW , ScheltemaN , ClercM , vanHoutenM , NibbelkeE , AchtenN , et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respiratory Medicine2020;8(10):1022-31. ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64. XuC , ScheltemaNM , QiC , VedderR , KleinLBC , NibbelkeEE ,  et al. Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age. European Respiratory Journal2019;54:PA4999. ">Blanken 2013</a>). Palivizumab reduces the daily rate of wheezing compared to placebo or no intervention at one year's follow‐up (RR 0.39, 95% CI 0.35 to 0.44; <a href="./references#CD013757-fig-0010" title="">Analysis 1.8</a>) We assessed the evidence for this outcome as of high certainty.  </p> </section> <section id="CD013757-sec-0066"> <h6 class="title">1.9 Days of supplemental oxygen</h6> <p>Two studies with 2789 participants reported this outcome (<a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>). Palivizumab may result in little to no difference in days of supplemental oxygen compared to placebo or no intervention at 150 days' follow‐up (MD ‐36.85, 95% CI ‐85.19 to 11.49; I² = 59%; <a href="./references#CD013757-fig-0011" title="">Analysis 1.9</a>).  </p> </section> <section id="CD013757-sec-0067"> <h6 class="title">1.10 Intensive care unit length of stay</h6> <p>Two studies with 2789 participants reported this outcome (<a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>). Palivizumab may result in little to no difference in intensive care unit length of stay compared to placebo or no intervention at 150 days' follow‐up (MD ‐13.51, 95% CI ‐61.11 to 34.08; I² = 50%; <a href="./references#CD013757-fig-0012" title="">Analysis 1.10</a>).  </p> </section> <section id="CD013757-sec-0068"> <h6 class="title">1.11 Mechanical ventilation days</h6> <p>Two studies with 2789 participants reported this outcome (<a href="./references#CD013757-bbs2-0002" title="FeltesTF , CabalkaAK , MeissnerC , PiazzaFM , CarlinDA , TopFH , et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics2003;143(4):532-40. ">Feltes 2003</a>; <a href="./references#CD013757-bbs2-0003" title="ForbesM , KumarV , YogevR , WuX , RobbieG , AmbroseC . Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Human Vaccines &amp; Immunotherapeutics2014;10(10):2789-94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998;102(3 Pt 1):531-7. ">IMpact‐RSV Study Group 1998</a>). Palivizumab may result in little to no difference in mechanical ventilation days compared to placebo or no intervention at 150 days' follow‐up (MD 5.78, 95% CI ‐10.37 to 21.92; I² = 0%; <a href="./references#CD013757-fig-0013" title="">Analysis 1.11</a>).  </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013757-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013757-sec-0069"></div> <section id="CD013757-sec-0070"> <h3 class="title" id="CD013757-sec-0070">Summary of main results</h3> <p>We included five studies with a total of 3343 participants assessing the effect of palivizumab compared to placebo or no intervention for preventing severe RSV infection in children. The certainty of the evidence for most outcomes was moderate to high. Palivizumab reduces hospitalisation due to RSV infection (high certainty evidence) and probably results in a slight reduction in hospitalisation due to respiratory‐related illness at two years' follow‐up (moderate certainty evidence). Palivizumab probably results in little to no difference in mortality and adverse events and may result in little to no difference in length of hospital stay, days of supplemental oxygen, length of stay in the ICU, and mechanical ventilation days at 150 days' follow‐up (low to moderate certainty evidence). Palivizumab may result in a large reduction in RSV infection at two years' follow‐up (low certainty evidence). Palivizumab reduces the number of wheezing days at one year's follow‐up (high certainty evidence).  </p> </section> <section id="CD013757-sec-0071"> <h3 class="title" id="CD013757-sec-0071">Overall completeness and applicability of evidence</h3> <p>Participants in the included studies were similar to those that would be found in clinical practice, that is with a higher risk of severe RSV infection. The studies were conducted mainly in children and infants from six to 12 months old at the beginning of the RSV season. Two studies included participants with bronchopulmonary dysplasia and one study included participants with CHD, which might introduce a source of clinical heterogeneity. We deemed this not important for most outcomes. Most of the included studies delivered palivizumab intramuscularly, which is the current preferred route of administration (only one study delivered palivizumab intravenously).  </p> <p>Most studies reported all of the outcomes of interest in this review. We found heterogeneity in outcomes definitions amongst studies. Some outcomes reported hospitalisations under adverse events. Nevertheless, we were able to extract and analyse the available data accordingly.   </p> <p>Consistent with the 2013 Cochrane Review (<a href="./references#CD013757-bbs2-0021" title="AndabakaT , NickersonJW , Rojas-ReyesMX , RuedaJD , Bacic VrcaV , BarsicB . Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database of Systematic Reviews2013, Issue 4. Art. No: CD006602. [DOI: 10.1002/14651858.CD006602.pub4]">Andabaka 2013</a>), palivizumab reduced the risk for RSV‐related hospitalisation, presenting similar statistical results. This conclusion reinforces the safety and efficacy of its use in high‐risk children, in line with the different existing guidelines recommending its use (<a href="./references#CD013757-bbs2-0029" title="BradyMT ,  Byington CL, DaviesHD , EdwardsKM , JacksonMA ,  Maldonado YA, et al, on behalf of American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics2014;134(2):415-20.">Brady 2014</a>). Furthermore, these updated findings are of paramount significance in the context of the changing landscape of RSV preventive interventions, including a new single‐dose monoclonal antibody against RSV fusion protein (nirsevimab) that successfully diminished the incidence of RSV‐associated lower respiratory tract infection episodes and hospitalisations (<a href="./references#CD013757-bbs2-0050" title="GriffinMP , YuanY , TakasT , DomachowskeJB , MadhiSA , ManzoniP , et al. Single-dose nirsevimab for prevention of RSV in preterm infants. New England Journal of Medicine2020;383(5):415-25. [DOI: 10.1056/NEJMoa1913556]">Griffin 2020</a>). </p> <p>Interestingly, we found that palivizumab resulted in a higher reduction in hospitalisation due to respiratory‐related illness in LMIC than in HIC. This finding is aligned with the higher burden of RSV disease described in LMIC (<a href="./references#CD013757-bbs2-0093" title="ShiT , McAllisterDA , O'BrienKL , SimoesEA , MadhiSA , GessnerBD , et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet2017;390(10098):946-58.">Shi 2017</a>). Moreover, a recent randomised clinical trial using a single intramuscular dose of RSV fusion protein nanoparticle vaccine in pregnant women showed a higher vaccine efficacy against RSV‐associated lower respiratory tract infection in LMIC than in HIC (<a href="./references#CD013757-bbs2-0068" title="MadhiS , PolackF , PiedraP , MunozF , TrenholmeA , SimõesE , et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. New England Journal of Medicine2020;383(5):426-39.">Madhi 2020</a>). The effect of palivizumab on mortality was downgraded due to imprecision, which may also be due to the fact that the included studies were not from LMIC, and the overall mortality was low. </p> <p>Palivizumab also resulted in a reduction in the number of wheezing days during the first year of life, in line with similar probe studies assessing this outcome (<a href="./references#CD013757-bbs2-0112" title="YoshiharaS , KusudaS , MochizukiH , OkadaK , NishimaS , SimõesE . Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics2013;132(5):811.">Yoshihara 2013</a>). Being able to prevent recurrent wheezing is of great impact in preschoolers since it is one of the most frequent chronic pathologies in that age range (<a href="./references#CD013757-bbs2-0100" title="SteinRT , SherrillD , MorganWJ , HolbergCJ , HalonenM , TaussigLM , et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet1999;354(9178):541-45. [PMID: 10470697]">Stein 1999</a>). Despite these encouraging results, in two follow‐up studies, no differences in the diagnosis of asthma were seen at age six after the use of palivizumab (<a href="./references#CD013757-bbs2-0072" title="MochizukiH , KusudaS , OkadaK , YoshiharaS , FuruyaH , Simões E et al. Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing. Six-year follow-up study. American Journal of Respiratory and Critical Care Medicine2017;196(1):29-38.">Mochizuki 2017</a>; <a href="./references#CD013757-bbs2-0090" title="ScheltemaNM , NibbelkeEE , PouwJ , BlankenMO , RoversMM , NaaktgeborenCA , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Medicine2018;6(4):257-64.">Scheltema 2018</a>), although the effects of palivizumab on the subsequent diagnosis of asthma may be differ depending on the atopic status of the studied individuals (<a href="./references#CD013757-bbs2-0095" title="SimõesEA , Carbonell-EstranyX , RiegerCH , MitchellI , FredrickL , GroothuisJR , for the Palivizumab Long-Term Respiratory Outcomes Study Group. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. Journal of Allergy and Clinical Immunology2010;126(2):256-62.">Simões 2010</a>). </p> </section> <section id="CD013757-sec-0072"> <h3 class="title" id="CD013757-sec-0072">Quality of the evidence</h3> <p>The overall certainty of the evidence was moderate to high. Most outcomes reported in the studies were assessed as low risk of bias. A common problem found in several of the included studies was the incomplete reporting of dispersion measures that were not provided, leading us to calculate standard deviation converted from P values and thus making us less confident about the precision of the results. Some studies were very small and had few events which led to important imprecision. We were unable to assess publication bias due to the scarcity of studies per outcome. </p> </section> <section id="CD013757-sec-0073"> <h3 class="title" id="CD013757-sec-0073">Potential biases in the review process</h3> <p>We rearranged the mortality outcome to maximise the use of available data. We took precautions to avoid bias in this process by documenting all changes in the Differences between protocol and review section of the review. We found that several outcomes were reported in a subset of patients, such as hospitalised patients. As there were no data regarding all randomised participants  in these cases, we decided to consider them as trials' exploratory analyses.  </p> <p>We followed the guidelines in Section 6.5<i> </i> of the <i>CochraneHandbook</i> to obtain the standard deviation converted from P values (<a href="./references#CD013757-bbs2-0058" title="HigginsJP , EldridgeS , LiT . Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook/archive/v6.">Higgins 2019c</a>). We assumed a normal distribution of the available data. However, the probability of non‐normal distribution of data remains, as no precise evidence of normal distribution could be found in the trial reports.  </p> </section> <section id="CD013757-sec-0074"> <h3 class="title" id="CD013757-sec-0074">Agreements and disagreements with other studies or reviews</h3> <p>A previous Cochrane Review incorporating most of the studies included in our review found that palivizumab prophylaxis was effective in reducing the frequency of hospitalisations due to RSV infection and reducing the incidence of severe lower respiratory tract RSV disease in children with chronic lung disease, congenital heart disease or those born prematurely (<a href="./references#CD013757-bbs2-0021" title="AndabakaT , NickersonJW , Rojas-ReyesMX , RuedaJD , Bacic VrcaV , BarsicB . Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database of Systematic Reviews2013, Issue 4. Art. No: CD006602. [DOI: 10.1002/14651858.CD006602.pub4]">Andabaka 2013</a>). However, the comparators considered in <a href="./references#CD013757-bbs2-0021" title="AndabakaT , NickersonJW , Rojas-ReyesMX , RuedaJD , Bacic VrcaV , BarsicB . Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database of Systematic Reviews2013, Issue 4. Art. No: CD006602. [DOI: 10.1002/14651858.CD006602.pub4]">Andabaka 2013</a> differed from those in our review. </p> <p>A previous non‐Cochrane systematic review included all of the studies in our review (<a href="./references#CD013757-bbs2-0109" title="WegzynC , TohL , NotarioG , BiguenetS , UnnebrinkK , ParkC , et al. Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review. Infectious Diseases and Therapy2014;3(2):133-58.">Wegzyn 2014</a>). Although our review did not include any new studies, we expanded the available knowledge related to the effect of palivizumab on different outcomes not considered in the previously mentioned review (<a href="./references#CD013757-bbs2-0109" title="WegzynC , TohL , NotarioG , BiguenetS , UnnebrinkK , ParkC , et al. Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review. Infectious Diseases and Therapy2014;3(2):133-58.">Wegzyn 2014</a>), such as the number of wheezing days. Furthermore, our review adds the risk of bias and certainty of the evidence assessments, which may be useful for decision‐makers in the clinical setting and may also guide the design of future research.   </p> <p>One review found similar results regarding all‐cause mortality and RSV hospitalisation amongst preterm infants at high risk (<a href="./references#CD013757-bbs2-0034" title="ChecchiaPA , NalysnykL , FernandesAW , MahadeviaPJ , XuY , FahrbachK , et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatric Critical Care Medicine2011;12(5):580-8.">Checchia 2011</a>); however, it included observational studies, both prospective and retrospective, and found mortality and hospitalisation rates lower than those found in our study. Another review found that prophylaxis with palivizumab reduced hospital admissions in preterm infants with or without chronic lung disease (<a href="./references#CD013757-bbs2-0108" title="WangD , CumminsC , BaylissS , SandercockJ , BurlsA . Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technology Assessment2008;12:36.">Wang 2008</a>). It also found that palivizumab reduced hospitalisation rate due to RSV amongst children with congenital heart disease. None of these non‐Cochrane systematic reviews were of high quality, and none of them incorporated GRADE methods in assessing the certainty of the evidence. </p> <p>We found additional systematic reviews and health technology assessments concluding that palivizumab is effective in reducing hospital stay and risk of admission in children with congenital heart disease (<a href="./references#CD013757-bbs2-0054" title="HarrisKC , AnisAH , CrosbyMC , CenderLM , PottsJE , HumanDG . Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective. Canadian Journal of Cardiology2011;27(4):523.e11-5.">Harris 2011</a>),  prematurely born infants, infants with lung complications, and infants from remote communities (<a href="./references#CD013757-bbs2-0067" title="MacS , SumnerA , Duchesne-BelangerS , StirlingR , TunisM , SanderB . Cost-effectiveness of palivizumab for respiratory syncytial virus: a systematic review. Pediatrics2019;143(5):e20184064.">Mac 2019</a>), but did not provide value for money because of its exceptionally high cost (<a href="./references#CD013757-bbs2-0054" title="HarrisKC , AnisAH , CrosbyMC , CenderLM , PottsJE , HumanDG . Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective. Canadian Journal of Cardiology2011;27(4):523.e11-5.">Harris 2011</a>). In this regard, a previous Cochrane Review found inconsistencies in palivizumab's cost‐effectiveness, due to wide variations in incremental cost‐effectiveness ratios (ICER), arising from different mortality rates, time horizons, and stakeholders' perspectives used in economic models (<a href="./references#CD013757-bbs2-0021" title="AndabakaT , NickersonJW , Rojas-ReyesMX , RuedaJD , Bacic VrcaV , BarsicB . Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database of Systematic Reviews2013, Issue 4. Art. No: CD006602. [DOI: 10.1002/14651858.CD006602.pub4]">Andabaka 2013</a>).  </p> <p>No previous review reported results for the number of wheezing days. This is a major issue, given the spreading hypothesis and studies suggesting that RSV infection is a risk factor for recurrent wheezing amongst infants and young children (<a href="./references#CD013757-bbs2-0088" title="SchauerU , HoffjanS , BittscheidtJ , KöchlingA , HemmisS , BongartzS , et al. RSV bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life. European Respiratory Journal2002;20(5):1277.">Schauer 2002</a>).  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013757-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram " data-id="CD013757-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full#CD013757-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013757-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Screen4Me summary diagram" data-id="CD013757-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Screen4Me summary diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full#CD013757-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013757-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Palivizumab versus placebo or no intervention, Outcome 1: Hospitalisation due to RSV infection" data-id="CD013757-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Palivizumab versus placebo or no intervention, Outcome 1: Hospitalisation due to RSV infection </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#CD013757-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013757-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Palivizumab versus placebo or no intervention, Outcome 2: Mortality" data-id="CD013757-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Palivizumab versus placebo or no intervention, Outcome 2: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#CD013757-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013757-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Palivizumab versus placebo or no intervention, Outcome 3: Adverse events" data-id="CD013757-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Palivizumab versus placebo or no intervention, Outcome 3: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#CD013757-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013757-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Palivizumab versus placebo or no intervention, Outcome 4: Hospitalisation due to respiratory‐related illness" data-id="CD013757-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Palivizumab versus placebo or no intervention, Outcome 4: Hospitalisation due to respiratory‐related illness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#CD013757-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013757-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Palivizumab versus placebo or no intervention, Outcome 5: Subgroup analysis: hospitalisation due to respiratory‐related illness" data-id="CD013757-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Palivizumab versus placebo or no intervention, Outcome 5: Subgroup analysis: hospitalisation due to respiratory‐related illness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#CD013757-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013757-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Palivizumab versus placebo or no intervention, Outcome 6: Length of hospital stay " data-id="CD013757-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Palivizumab versus placebo or no intervention, Outcome 6: Length of hospital stay  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#CD013757-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013757-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Palivizumab versus placebo or no intervention, Outcome 7: RSV infection" data-id="CD013757-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Palivizumab versus placebo or no intervention, Outcome 7: RSV infection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#CD013757-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013757-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Palivizumab versus placebo or no intervention, Outcome 8: Number of wheezing days" data-id="CD013757-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Palivizumab versus placebo or no intervention, Outcome 8: Number of wheezing days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#CD013757-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013757-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Palivizumab versus placebo or no intervention, Outcome 9: Days of supplemental oxygen" data-id="CD013757-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Palivizumab versus placebo or no intervention, Outcome 9: Days of supplemental oxygen </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#CD013757-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013757-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Palivizumab versus placebo or no intervention, Outcome 10: Intensive care unit length of stay" data-id="CD013757-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Palivizumab versus placebo or no intervention, Outcome 10: Intensive care unit length of stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#CD013757-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013757-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/urn:x-wiley:14651858:media:CD013757:CD013757-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Palivizumab versus placebo or no intervention, Outcome 11: Mechanical ventilation days" data-id="CD013757-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_t/tCD013757-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Palivizumab versus placebo or no intervention, Outcome 11: Mechanical ventilation days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#CD013757-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/media/CDSR/CD013757/image_n/nCD013757-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013757-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Palivizumab compared to placebo, no intervention or standard care for preventing respiratory syncytial virus (RSV) infection in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Palivizumab compared to placebo, no intervention or standard care for preventing respiratory syncytial virus (RSV) infection in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children (0 to 24 months) </p> <p><b>Setting</b>: inpatients and outpatients </p> <p><b>Intervention</b>: palivizumab   </p> <p><b>Comparison</b>: placebo, no intervention or standard care   </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Outcomes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Relative effect<br/>(95% CI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>№ of participants<br/>(studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Certainty of the evidence<br/>(GRADE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Comments</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with palivizumab</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospitalisation due to RSV infection</b> </p> <p><i>Follow‐up:  2 years</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>98 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b><br/>(29 to 62) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.44</b><br/>(0.30 to 0.64) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3343<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁⨁<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> <p><i>Follow‐up:  2 years</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b><br/>(10 to 27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.69</b><br/>(0.42 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3343<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁◯<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p><i>Follow‐up: 150 days</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>84 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b><br/>(71 to 117) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.09</b><br/>(0.85 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2831<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁◯<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospitalisation due to respiratory‐related illness</b> </p> <p><i>Follow‐up: 2 years</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>351 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>274 per 1000</b><br/>(218 to 340) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.78</b><br/>(0.62 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3343<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁◯<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RSV infection</b> </p> <p><i>Assessed with: incidence of laboratory‐confirmed RSV‐bronchiolitis</i> </p> <p><i>Follow‐up: 2 years</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>195 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b><br/>(39 to 107) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.33</b><br/>(0.20 to 0.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>554<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁◯◯<br/>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of wheezing days</b> </p> <p><i>Assessed with: rates of wheezing per day</i> </p> <p><i>Follow‐up: 12 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>45 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b><br/>(16 to 19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.39</b><br/>(0.35 to 0.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁⨁<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level due to imprecision. The 95% confidence interval includes appreciable benefit and little to no effect.<br/><sup>b</sup>Downgraded 1 level due to imprecision. The 95% confidence interval includes appreciable benefit and harm.<br/><sup>c</sup>Downgraded 2 levels due to few number of events and participants in both groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Palivizumab compared to placebo, no intervention or standard care for preventing respiratory syncytial virus (RSV) infection in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/full#CD013757-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013757-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Palivizumab versus placebo or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Hospitalisation due to RSV infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.30, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.42, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.85, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Hospitalisation due to respiratory‐related illness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.62, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Subgroup analysis: hospitalisation due to respiratory‐related illness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.62, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.65, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Low‐ and middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.18, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Length of hospital stay  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐42.24 [‐84.77, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 RSV infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.20, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Number of wheezing days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.35, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Days of supplemental oxygen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐36.85 [‐85.19, 11.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Intensive care unit length of stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.51 [‐61.11, 34.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Mechanical ventilation days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.78 [‐10.37, 21.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Palivizumab versus placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#CD013757-tbl-0002">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Hospitalisation due to RSV infection</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Blanken 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study does not adequately describe the randomisation process, although there are no serious concerns regarding baseline differences. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were analysed in accordance with the pre‐specified plan and assessed based on pre‐specified domains and time‐points.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Feltes 2003</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences.  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>IMpact‐RSV Study Group 1998</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Subramanian 1998</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences.  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Tavsu 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study does not adequately describe the randomisation process, although there are no serious concerns regarding baseline differences. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and carers were aware of the assigned intervention. There were no deviations from intended interventions. There is no information regarding the analyses used.  </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to raise some concerns because of issues related to the randomisation process and awareness of assigned interventions.  </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Hospitalisation due to RSV infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Mortality</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Blanken 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study does not adequately describe the randomisation process, although there are no serious concerns regarding baseline differences. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were analysed in accordance with the pre‐specified plan and assessed based on pre‐specified domains and time‐points.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Feltes 2003</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences.  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>IMpact‐RSV Study Group 1998</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Subramanian 1998</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences.  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Tavsu 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study does not adequately describe the randomisation process, although there are no serious concerns regarding baseline differences. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and carers were aware of the assigned intervention. There were no deviations from intended interventions. There is no information regarding the analyses used.  </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to raise some concerns because of issues related to the randomisation process and awareness of assigned interventions.  </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Feltes 2003</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences.  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>IMpact‐RSV Study Group 1998</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Subramanian 1998</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences.  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Hospitalisation due to respiratory‐related illness</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Blanken 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study does not adequately describe the randomisation process, although there are no serious concerns regarding baseline differences. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were analysed in accordance with the pre‐specified plan and assessed based on pre‐specified domains and time‐points. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Feltes 2003</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences.  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>IMpact‐RSV Study Group 1998</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Subramanian 1998</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences.  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Tavsu 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study does not adequately describe the randomisation process, although there are no serious concerns regarding baseline differences. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and carers were aware of the assigned intervention. There were no deviations from intended interventions. There is no information regarding the analyses used.  </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to raise some concerns because of issues related to the randomisation process and awareness of assigned interventions.  </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Hospitalisation due to respiratory‐related illness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Subgroup analysis: hospitalisation due to respiratory‐related illness</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.5.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Blanken 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study does not adequately describe the randomisation process, although there are no serious concerns regarding baseline differences. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were analysed in accordance with the pre‐specified plan and assessed based on pre‐specified domains and time‐points. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Feltes 2003</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences.  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>IMpact‐RSV Study Group 1998</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Subramanian 1998</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences.  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.5.2 Low‐ and middle‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Tavsu 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study does not adequately describe the randomisation process, although there are no serious concerns regarding baseline differences. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and carers were aware of the assigned intervention. There were no deviations from intended interventions. There is no information regarding the analyses used.  </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomized participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to raise some concerns because of issues related to the randomization process and awareness of assigned interventions.  </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Subgroup analysis: hospitalisation due to respiratory‐related illness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 RSV infection</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Blanken 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study does not adequately describe the randomisation process, although there are no serious concerns regarding baseline differences. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were analysed in accordance with the pre‐specified plan and assessed based on pre‐specified domains and time‐points.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Subramanian 1998</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation and allocation were done centrally and there are no concerns regarding baseline differences.  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. </p> </td> </tr> <tr class="study-data"> <td> <p>Tavsu 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study does not adequately describe the randomisation process, although there are no serious concerns regarding baseline differences. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and carers were aware of the assigned intervention. There were no deviations from intended interventions. There is no information regarding the analyses used.  </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomised participants. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified analysis plan available, but the outcome is usually measured and analysed in the way presented in the trial.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to raise some concerns because of issues related to the randomisation process and awareness of assigned interventions.  </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 RSV infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Number of wheezing days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Blanken 2013</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study does not adequately describe the randomisation process, although there are no serious concerns regarding baseline differences. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those involved in caring for participants were not aware of the assigned intervention. There are no concerns regarding the analysis used to estimate the effect of assignment to intervention.   </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is a high proportion of missing data and authors performed no analyses to correct it due that most losses took place prior to commencing treatment (adequate post‐randomisation exclusions).  </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Method for outcome measurement was appropriate and equally applied between groups. Outcome assessors were blinded to intervention status.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were analysed in accordance with the pre‐specified plan and assessed based on pre‐specified domains and time‐points.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Number of wheezing days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013757.pub2/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013757.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013757-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013757-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013757-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013757-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD013757-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013757-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013757-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013757-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013757-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013757\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013757\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013757\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013757\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013757\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013757.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013757.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013757.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013757.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013757.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718545564"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013757.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718545568"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013757.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd2f61fcaf401',t:'MTc0MDcxODU0NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 